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A B S T R A C T
Background
Oxygen (O2) is widely used in people with acute myocardial infarction (AMI). Previous systematic reviews concluded that there was
insufficient evidence to know whether oxygen reduced, increased or had no effect on heart ischaemia or infarct size. Our first Cochrane
review in 2010 also concluded there was insufficient evidence to know whether oxygen should be used. Since 2010, the lack of evidence
to support this widely used intervention has attracted considerable attention, prompting further trials of oxygen therapy in myocardial
infarction patients. It is thus important to update this Cochrane review.
Objectives
To assess the effects of routine use of inhaled oxygen for acute myocardial infarction (AMI).
Search methods
We searched the following bibliographic databases on 6 June 2015: the Cochrane Central Register of Controlled Trials (CENTRAL) in
the Cochrane Library, MEDLINE (OVID), Embase (OVID), CINAHL (EBSCO) and Web of Science (Thomson Reuters). LILACS
(Latin American and Caribbean Health Sciences Literature) was last searched in September 2016. We also contacted experts to identify
eligible studies. We applied no language restrictions.
Selection criteria
Randomised controlled trials in people with suspected or proven AMI (ST-segment elevation myocardial infarction (STEMI) or non-
STEMI) within 24 hours after onset, in which the intervention was inhaled oxygen (at normal pressure) compared to air, regardless of
co-therapies provided to participants in both arms of the trial.
Data collection and analysis
Twoauthors independently reviewed the titles and abstracts of identified studies to see if theymet the inclusion criteria and independently
undertook the data extraction. We assessed the quality of studies and the risk of bias according to guidance in the Cochrane Handbook
for Systematic Reviews of Interventions. The primary outcome was death. The measure of effect used was the risk ratio (RR) with a 95%
confidence interval (CI). We used the GRADE approach to evaluate the quality of the evidence and the GRADE profiler (GRADEpro)
to import data from Review Manager 5 and create ’Summary of findings’ tables.
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Main results
The updated search yielded one new trial, for a total of five included studies involving 1173 participants, 32 of whom died. The pooled
risk ratio (RR) of all-cause mortality in the intention-to-treat analysis was 0.99 (95% CI 0.50 to 1.95; 4 studies, N = 1123; I2 = 46%;
quality of evidence: very low) and 1.02 (95% CI 0.52 to 1.98; 4 studies, N = 871; I2 = 49%; quality of evidence: very low) when only
analysing participants with confirmed AMI. One trial measured pain directly, and two others measured it by opiate usage. The trial
showed no effect, with a pooled RR of 0.97 for the use of opiates (95% CI 0.78 to 1.20; 2 studies, N = 250). The result on mortality
and pain are inconclusive. There is no clear effect for oxygen on infarct size (the evidence is inconsistent and low quality).
Authors’ conclusions
There is no evidence from randomised controlled trials to support the routine use of inhaled oxygen in people with AMI, and we cannot
rule out a harmful effect. Given the uncertainty surrounding the effect of oxygen therapy on all-cause mortality and on other outcomes
critical for clinical decision, well-conducted, high quality randomised controlled trials are urgently required to inform guidelines in
order to give definitive recommendations about the routine use of oxygen in AMI.
P L A I N L A N G U A G E S U M M A R Y
Routine use of oxygen in people who have had a heart attack
Background
Many people who are having a heart attack are routinely given oxygen to breathe.
Review question
We looked for the evidence to support this longstanding practice by searching for randomised controlled trials that compared the
outcomes for people given oxygen versus normal air to breathe. We were primarily interested in seeing whether there was a difference
in the number of people who died, but we also looked at whether administering oxygen reduced pain or other adverse outcomes.
Key results
We found five randomised controlled trials that compared people with suspected or proven heart attack who were given oxygen to a
similar group of people who were given air (evidence is current to June 2016). These trials involved a total of 1173 participants, 32 of
whom died. There were similar death rates in both groups, suggesting oxygen neither helps nor harms, but the trials are not big enough
to know for sure. Moreover, it is possible that more heart muscle might be damaged in people given oxygen than in people given air.
Conclusion
Since there is no evidence whether the oxygen is good or harmful in this clinical condition, it is important to test oxygen in a big trial
as soon as possible to be sure that this common treatment is doing more good than harm in people who are having a heart attack.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oxygen versus air for acute myocardial infarction
Patient or population: people with acute myocardial infarct ion
Settings: pre-hospital and hospital
Intervention: oxygen
Comparison: air
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Air (or titrated oxygen) Oxygen
All- cause mortality in
hospital for partici-
pants with AM I
Follow-up: 4 weeks
Study population RR 1.02
(0.52 to 1.98)
871
(4 studies)
⊕©©©
Very lowa
-
36 per 1000 37 per 1000
(19 to 71)
M oderate population
34 per 1000 35 per 1000
(18 to 67)
All-
cause mortality in hos-
pital for all participants
(including those with-
out confirmed AM I)
Follow-up: 4 weeks
Study population RR 0.99
(0.50 to 1.95)
1123
(4 studies)
⊕©©©
Very lowb
-
28 per 1000 28 per 1000
(14 to 55)
M oderate population
29 per 1000 29 per 1000
(15 to 57)
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All- cause mortality in
hospital for all partici-
pants (including those
without confirmed
AM I) trials done in the
revascularisation era
Follow-up: 4 weeks
Study population population RR 0.58
(0.24 to 1.39)
923
(3 studies)
⊕⊕©©
Lowc
-
27 per 1000 16 per 1000
(7 to 38)
M oderate population
26 per 1000 15 per 1000
(6 to 36)
Opiate use (as a proxy
measure for pain) for
all participants on ITT
(including those with-
out confirmed AM I)
Follow-up: 4 weeks
Study population RR 0.97
(0.78 to 1.20)
250
(2 studies)
⊕⊕©©
Lowd
583 per 1000 566 per 1000
(455 to 700)
M oderate population
634 per 1000 615 per 1000
(495 to 761)
Recurrent myocardial
infarction (or is-
chaemia)
Follow-up 4 weeks
Study population RR 1.67
(0.94 to 2.99)
578
(2 studies)
⊕⊕⊕©
Lowe
-
64 per 1000 87 per 1000
(50 to 152)
M oderate population
140 per 1000 190 per 1000
(109 to 333)
Infarct size CK and
other enzymes
See comment See comment Not est imable 0
(2 studies)
⊕©©©
Low
The are slight inconsis-
tencies between 2 tri-
als with respect to the
ef fect of oxygen on CK
levels (Ukholkina 2005
and Stub 2015). There
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are inconsistency in the
ef fect of oxygen on CK
levels and the ef fect on
troponin I in Stub 2015
(whit in study inconsis-
tency).
Infarct size by M RI
(est imated 6 months af -
ter AMI)
See comment See comment Not est imable 0
(2 studies)
⊕©©©
Very low
The evidence for this
outcome comes f rom
2 randomised trials but
in ’selected’ groups
of pat ients,. As the
data comes f rom with
non-randomised com-
parisons and was per-
formed 6 months af -
ter AMI, we consid-
ered them unsuitable
for quant itat ive synthe-
sis
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
AM I: acute myocardial infarct ion; CI: conf idence interval; M RI: magnet ic resonance imaging; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aThe evidence for this outcome has very serious lim itat ions due to incomplete outcomes data in 2 of the 4 included studies
(Ranchord 2012; Ukholkina 2005); downgraded 2 levels. An addit ional level is applied for imprecision.
bDowngraded 2 levels for very serious lim itat ions due to incomplete data outcomes in 2 of 4 studies (Ranchord 2012;
Ukholkina 2005). An addit ional point deducted for imprecision.
cThe evidence for this outcome has serious lim itat ions due to incomplete data in 2 of the 3 studies (Ranchord 2012; Ukholkina
2005), but the other one study with low risk of bias is the most weighted in meta analysis (82.3%) (Stub 2015), so the quality
is downgraded 1 level. An addit ional point deducted for imprecision.
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dThe evidence for pain comes f rom a blinded study with unclear risk of bias and another unblinded study with high risk of
bias for a subject ive outcome; downgraded one level. An addit ional point deducted for indirectness (opiate is used as proxy
for pain).
eDowngraded for imprecision and for inconsistency
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B A C K G R O U N D
Description of the condition
Coronary heart disease (CHD) is an important cause of death
worldwide. Over 7 million people every year die from CHD, ac-
counting for 12.8% of all deaths (WHO 2011). It is the single
most common cause of death before the age of 75 in Europe
(Townsend 2015), and in the USA it accounted for around one of
every seven deaths in 2011 (Mozaffarian 2015), although deaths
from cardiovascular disease and CHD in men and women have
fallen in most developed countries. For example, rates of CHD
deaths per million in men without diabetes in England fell by
more than half between 1995 and 2010 (Ecclestone 2015). Ac-
cording to the Euro Heart Survey of acute myocardial infarction
(AMI) in 47 countries (Puymirat 2013), in-hospital mortality was
6.2%. Approximately 45% of the reduction in CHD mortality
is attributable to improvement in medical therapies for coronary
disease (Capewell 2000).
A common manifestation of CHD, often the first, is AMI. The
third Global MI Task Force defines AMI as “any evidence of my-
ocardial necrosis in a clinical setting consistent with acute myocar-
dial ischaemia” (Thygesen 2012).
Myocardial ischaemia is usually the result of spontaneous com-
plications of atherosclerosis (plaque rupture, ulceration, fissur-
ing, erosion or dissection) resulting in coronary thrombosis (type
1 AMI). Other categories of AMI include: those produced by
underlying CHD with an ischaemic imbalance attributable to a
wide range of factors including endothelial dysfunction, coronary
spasm, coronary embolism, tachy-/brady-arrhythmias and hypo-
and hypertension (type 2 AMI); sudden cardiac death induced by
myocardial ischaemia (type 3 AMI); and AMI occurring in the
context of invasive coronary procedures such as percutaneous coro-
nary intervention (PCI), in-stent thrombosis, or coronary artery
bypass grafting (CABG), categorised as subtypes 4a, 4b and 5 of
AMI. By far the most common types of AMI are types 1 and 2,
to such an extent that their incidence may be used as proxy vari-
ables to estimate the prevalence of CHD in the general popula-
tion. Hereafter we will use the term ’AMI’ to refer the type 1 and
type 2 AMI.
Myocardial injury may be detected through: highly sensitive bio-
chemical markers such as troponin (I or T), or the MB fraction
of the creatine kinase (CK-MB); electrocardiographic changes;
or imaging techniques such as echocardiography, magnetic reso-
nance imaging (MRI) or radionuclide imaging. Necessary criteria
to diagnose AMI in a clinical context include a change (rise and/
or fall) in cardiac biomarker values, together with at least one of
the following: ischaemic symptoms, typical electrocardiographic
changes, or abnormalities in the structure or wall motion of the
heart identified by imaging techniques.
Moreover, the recognition that acute coronary syndromes rep-
resent a spectrum of pathophysiological processes rather than a
uniform type of ’heart attack’ has led to publication of separate
guidelines with different therapeutic options for AMI presenting
with persistent ST-segment elevation (STEMI) and non-STEMI
(NSTEMI) presentations.
The in-hospital mortality rate of unselected STEMI patients ac-
cording to the Euro Heart Survey, published by the European So-
ciety of Cardiology, varies between 6% and 14% (Mandelzweig
2006). The most serious complications of AMI are cardiogenic
shock, heart failure, ventricular fibrillation and recurrent is-
chaemia. Around 8% of people with AMI develop cardiogenic
shock (Babaev 2005), but this remains present in 29% of those
people on admission to hospital. The Global Registry of Acute
Coronary Events (GRACE) reported that heart failure occurred in
15.6% of people with STEMI and 15.7% of those with NSTEMI,
but heart failure was present in only 13% of these patients on ad-
mission to hospital (Steg 2004). Ventricular fibrillation occurred
in 1.9% of people with AMI (Goldberg 2008), and 21% of those
with acute coronary syndromes presentedwith recurrent ischaemia
(Yan 2010), about half of whom experienced this outcome in the
first 24 hours. Other possible complications of AMI include peri-
carditis, mitral insufficiency, arrhythmias and conduction distur-
bances.
The cornerstone of contemporary management of people with
STEMI is reperfusion therapy, with either primary percutaneous
coronary intervention (PCI) or thrombolytic treatment if less than
12 hours has elapsed from the onset of symptoms. Other recom-
mended treatments in international guidelines include morphine,
oxygen (O2), nitrates and aspirin (MONA) (O’Connor 2010;
O’Gara 2013; StegG 2012). Some of these treatments have a well-
established research base, while others do not (Nikolaou 2012;
O’Driscoll 2008; SIGN 2010).
Description of the intervention
Inhaled oxygen at normal pressure delivered by face mask or nasal
cannula, at any concentration.
How the intervention might work
Myocardial infarction occurs when the flow of oxygenated blood
in the heart is interrupted for a sustained period of time. The ra-
tionale for providing supplemental oxygen to a person with AMI
is that it may improve the oxygenation of the ischaemic myocar-
dial tissue and reduce ischaemic symptoms (pain), infarct size and
consequent morbidity and mortality.
Why it is important to do this review
Although it is biologically plausible that oxygen is helpful, it is also
biologically plausible that it may be harmful. Potentially harm-
ful mechanisms include the paradoxical effect of oxygen in reduc-
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ing coronary artery blood flow and increasing coronary vascular
resistance, measured by intracoronary Doppler ultrasonography
(McNulty 2005; McNulty 2007); reduced stroke volume and car-
diac output (Milone 1999); other adverse haemodynamic conse-
quences, such as increased vascular resistance from hyperoxia; and
reperfusion injury from increased oxygen free radicals (Rousseau
2005), which may also have adverse electrophysiological effects,
triggering lethal arrhythmias (Xie 2009).
A systematic review of human studies that included non-ran-
domised studies did not confirm that oxygen administration di-
minishes acute myocardial ischaemia (Nicholson 2004). Indeed,
some evidence suggested that oxygen may increase myocardial is-
chaemia (Nicholson 2004). Another narrative review of oxygen
therapy also sounded a cautionary note (Beasley 2007). It refer-
enced a randomised controlled trial (RCT) conducted in 1976
showing that the risk ratio (RR) of death was 2.89 (95% confi-
dence interval (CI) 0.81 to 10.27) in participants receiving oxy-
gen compared to those breathing air (Rawles 1976). While this
suggested that oxygen may be harmful, the increased risk of death
could easily have been a chance finding. A systematic review looked
at the effect of oxygen on infarct size in people with AMI and
concluded that “[t]here is little evidence by which to determine
the efficacy and safety of high flow oxygen therapy in MI. The
evidence that does exist suggests that the routine use of high flow
oxygen in uncomplicated AMI may result in a greater infarct size
and possibly increase the risk of mortality” (Wijesinghe 2009).
Despite this lack of robust evidence of effectiveness prior to the
publication of our 2010 Cochrane review of the evidence, inter-
national guidelines widely recommended oxygen administration
(AARC2002;AHA2005;Anderson 2007; Antman2002; ILCOR
2005; Van de Werf 2008). Some guidelines were more cautious;
for example, the European guideline did not recommend routine
oxygen use in acute coronary syndrome (ACS) (Bassand 2007),
and the Scottish IntercollegiateGuidelines Network (SIGN) guid-
ance only recommended oxygen use in hypoxaemia (< 90% sat-
uration), noting that there was no clinical evidence for its effec-
tiveness and referring to animal models that showed a reduction
in infarct size (SIGN 2007).
Guidelines published since the 2010 Cochrane review have tended
tomove to a more cautious position reflecting the lack of evidence.
In 2010, for example, the American Heart Association Guidelines
for Cardiopulmonary Resuscitation and Emergency Cardiovascu-
lar care stated that: “EMS providers administer oxygen during the
initial assessment of patients with suspected ACS. However, there
is insufficient evidence to support its routine use in uncomplicated
ACS. If the patient is dyspnoeic, hypoxaemic, or has obvious signs
of heart failure, providers should titrate therapy, based on moni-
toring of oxyhaemoglobin saturation, to 94% (class I, level of ev-
idence: C). Updated SIGN guidance states, ”A Cochrane review
found no conclusive evidence from randomised controlled trials
to support the routine use of inhaled oxygen in patients with AMI.
There is no evidence that routine administration of oxygen to all
patients with the broad spectrumof acute coronary syndromes im-
proves clinical outcome or reduces infarction size“ (SIGN 2010).
In 2011 an addendum to the National Heart Foundation of Aus-
tralia/Cardiac Society of Australia and New Zealand Guidelines
for the Management of Acute Coronary Syndromes (ACS), au-
thors stated that ”There is currently insufficient evidence to for-
mulate clear recommendations about oxygen therapy . . . Defini-
tive trials are needed to answer this question“ (Chew 2011).
Similarly, the 2012 ESC guidelines for STEMI, citing the
Cochrane review, now state: ”Oxygen (by mask or nasal prongs)
should be administered to those who are breathless, hypoxic, or
who have heart failure. Whether oxygen should be systematically
administered to patients without heart failure or dyspnoea is at
best uncertain. Noninvasive monitoring of blood oxygen satura-
tion greatly helps when deciding on the need to administer oxygen
or ventilator support“ (Steg G 2012).
The 2013 ACCF/AHA Guideline for the Management of ST El-
evation Myocardial Infarction shows a similar change in empha-
sis: ”Few data exist to support or refute the value of the routine
use of oxygen in the acute phase of STEMI, and more research
is needed. A pooled Cochrane analysis of 3 trials showed a 3-fold
higher risk of death for patients with confirmed AMI treated with
oxygen than for patients with AMImanaged on room air. Oxygen
therapy is appropriate for patients who are hypoxaemic (oxygen
saturation < 90%) and may have a salutary placebo effect in oth-
ers. Supplementary oxygen may, however, increase coronary vas-
cular resistance. Oxygen should be administered with caution to
patients with chronic obstructive pulmonary disease and carbon
dioxide retention“. (O’Gara 2013).
The British Heart Foundation (BHF), in response to the doubts
about oxygen use raised by Beasley 2007, originally stated in an ar-
ticle inThe Guardian in 2007 that ”[t]he current practice of giving
high-flow oxygen is an important part of heart attack treatment.
Best practice methods have been developed and refined over the
years to ensure the best possible outcome for patients. There is not
enough evidence to change the current use of oxygen therapy in
heart attacks“. Five years after the publication of the first Cochrane
Review, the use of oxygen in AMI and across the spectrum of coro-
nary acute syndromes is still controversial (Shuvy 2013).We think
that, given the evidence cited, it would have beenmore appropriate
to conclude that despite decades of use there is inadequate clinical
trial evidence to unequivocally support routine administration of
oxygen. The BHF subsequently stated that the 2010 Cochrane
review ”highlights the need for more research into the effects of
oxygen when it is given during a heart attack. Until recently, heart
attack patients were routinely treated with oxygen but we simply
do not have enough evidence to know if that treatment is benefi-
cial or harmful“ (BHF 2010).
Despite the attention given to the uncertainty around the role of
oxygen since our 2010 Cochrane review, practice appears to vary,
possibly because the evidence base informing current guideline
recommendations remains uncertain. A survey of 231 cardiac care
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units in the UK undertaken shortly after the 2010 review reported
that only a third adhered to guideline recommendations to titrate
oxygen to saturation rather than administer routinely, and prac-
tice was no different in hospitals that had formal oxygen therapy
policies versus those that did not (Ripley 2012).
With the lack of collective certainty about the use of oxygen, a
number of clinical trials are now underway or have recently been
reported to reassess this treatment. In general, practice should not
be based on tradition but on proven benefit and safety. Given that
the 1976 trial was suggestive of potential harm from oxygen in
suspected AMI (Rawles 1976), it is important to systematically
review and update the evidence base for current and future guid-
ance regarding the role of oxygen therapy in heart attack patients,
and if necessary, to undertake further research to clarify whether
this intervention does more harm than good. If the only robust
evidence is suggestive of potentially serious harm, even if the re-
sult is not statistically significant, it reinforces our opinion that
this intervention should not be routinely used, however sound the
pathophysiological reasoning.
O B J E C T I V E S
To assess the effects of routine use of inhaled oxygen for acute
myocardial infarction (AMI). Primary outcomes include death and
pain.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of parallel or cluster design,
in any language, with any length of follow-up, and with any pub-
lication status (full publication, abstract only or unpublished).
Types of participants
Adults of any age treated, in a pre-hospital or a hospital setting, for
suspected or proven AMI (STEMI or NSTEMI), within 24 hours
of symptoms onset, regardless of any co-therapy (for example a
reperfusion therapy) provided to both arms of the trial.
Types of interventions
The intervention is routinely given inhaled oxygen administered
by any device at normal pressure for one hour or more within 24
hours of AMI symptoms onset. The comparator is air, or air with
titrated oxygen in the event of desaturation.
Excluded interventions are hyperbaric oxygen or aqueous oxygen
therapy (unless the studies include arms with air or oxygen at
normal pressure).
Types of outcome measures
This review is primarily focused on clinically important outcomes.
To facilitate the assessment of the clinical importance of outcomes
we used the nine-point scale suggested byGRADE (Guyatt 2008),
which classifies the outcomes into three levels of importance. The
outcomes included in the review are type I (”critical for decision-
making“- ratings 9, 8, 7) and also type 2 (”important but not crit-
ical for decision-making“- ratings 6, 5, 4). We did not include the
type 3 outcomes: (”not important for decision-making, of lower
importance to patients“ - ratings 3, 2, 1).We pre-specifiedmortal-
ity as the primary outcome. We agreed the point on the GRADE
scale for each outcome through discussion within the review team,
where we easily reached a consensus. We showed our proposed
classifications to cardiologist colleagues to see whether they agreed
with them. Although there were one-point differences in some of
their assessments of the importance of particular outcomes, none
of these affected the level of importance into which we classified
an outcome.
We classified the following outcomes as type I (the review group’s
consensus score is given in brackets).
• All-cause mortality (9).
• Cardiac mortality (9).
• Cardiac failure (8).
• Stroke (8).
• Recurrence of myocardial infarction or ischaemia (8).
• Major bleeding (8).
• Pain (7).
• Revascularisation (7).
• Pericarditis (7).
• Arrhthymias (7).
We classified the following outcomes as type 2 outcomes.
• Left ventricular function (global and segmentary) (6).
• Infarct size, whether estimated using biological methods
(electrocardiogram (ECG), enzymes CK, CK-MB, troponin T or
troponin I, brain natriuretic peptide (BNP)) or imaging
techniques such as magnetic resonance imaging (MRI), or
echocardiography (5).
We classified the following outcomes as type 3 outcomes.
• ECG changes (4).
• Platelet aggregation (3).
• Biomarkers of oxidative stress (2).
• Apoptosis (2).
• Inflammation (2).
Although these outcomes may prove useful for helping understand
the disease process, they currently have little implication for deci-
sion-making or prognosis.
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We used standard direct measures for all types of outcomes. For
the case of pain, when the direct measurement was not available we
used the opiate dosage as a proxy for pain. This approach (response
to treatment) is classically used when validating pain scales. We
have included type 2 outcomes because they may be used to make
clinical decisions or recommendations.
Search methods for identification of studies
Electronic searches
We searched the followingbibliographic databases (from inception
to 6 June 2016).
• Cochrane Central Register of Controlled Trials
(CENTRAL, 2016, Issue 5) in the Cochrane Library.
• MEDLINE In-Process & Other Non-Indexed Citations
and MEDLINE Ovid (1946 to 6 June 2016).
• Embase Ovid (1980 to 2016 week 23).
• PubMed (2012 to 4 June 2015).
• CINAHL Plus (EBSCO, 1937 to 6 June 2016).
• Web of Science Core Collection (Thomson Reuters, 1970
to 6 June 2016).
We also searched LILACS (Latin American and Caribbean Health
Sciences Literature) in BIREME (Centro Latinoamericano y del
Caribe de Información en Ciencias de la Salud) from 2012 to 22
September 2016. (lilacs.bvsalud.org).
We applied the sensitivity-maximising version of the Cochrane
RCT search filter to the MEDLINE searches and its adaptations
to Embase, CINAHL Plus and Web of Science (Lefebvre 2011).
We searched the following databases for ongoing trials using the
search terms ”(Acute myocardial infarction ANDoxygen as search
strategy)“ (12 September 2016).
• Current Controlled Trials metaRegister (www.controlled-
trials.com/mrct).
• The European Union Clinical Trials Register (
www.clinicaltrialsregister.eu/about.html).
• International Clinical Trials Registry Platform (ICTRP),
World Health Organization (www.who.int/ictrp/network/en/)
Details of the database search strategies are in Appendix 1 (for
2010), Appendix 2 (for 2012), Appendix 3 (for 2015) and
Appendix 4 (for 2016).
Searching other resources
We searched proceedings of annual meetings and conferences of
professional bodies (American Heart Association, British Cardio-
vascular Society, European Society of Cardiology and American
College of Cardiology) for relevant abstracts (from August 2013
to 4 June 2015).
We contacted experts in the field to locate any unpublished studies
and checked citations from key references.
We applied no date or language restrictions to the searches.
Data collection and analysis
We used the standard methods of Cochrane as described in the
Cochrane Handbook for Systematic Reviews of Interventions so that
the review methods are consistent with current recommendations
(Higgins 2011). We used Review Manager 5 (RevMan 5) for the
analysis (RevMan 2014).
Selection of studies
Two authors independently reviewed the titles and abstracts of
studies identified in the searches to see if they met the above inclu-
sion criteria. We obtained study reports in full text when inclusion
could not be decided from the title or abstract.
Data extraction and management
Two authors independently evaluated the methodological quality
and undertook independent data extraction using an agreed data
extraction form. We resolved differences by discussion. One re-
view author entered the data into RevMan 2014, and two others
checked them.
Assessment of risk of bias in included studies
Risk of bias in individual studies
We used the two-part tool described in section 8.5 of Higgins
2011. We explored the six specific domains: sequence generation,
allocation concealment, blinding (participants, personnel and out-
come assessors), incomplete outcome data, selective outcome re-
porting, and other potential threats to validity.
For each trial, two review authors first independently described the
design characteristics relating to each domain and then judged the
risk of bias associated with the main outcome. We used a nominal
scale for the judgement: low, high or unclear risk of bias.
Risk of bias across studies
We did an overall assessment of risk of bias for every outcome
within the review for each domain, using a similar scale: low risk of
bias in all domains, unclear risk of bias for one or more domains,
and high risk of bias for one or more domains.
Whenwe undertookmeta-analysis, we summarised the risk of bias
for the main outcomes across studies. We resolved disagreements
between review authors in the description or in the judgement by
consensus, without the need for recourse to a third review author.
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Measures of treatment effect
We looked at the risk ratio (RR) of death and reported this rather
than the risk difference. We also looked for differences in mean
pain scores; if studies did not report these scores, we used the RR
of opiate use as a proxy measure for pain intensity. We used the
differences in mean for continuous measurement of infarct size
such as cardiac enzymes, troponin T, BNP or MRI.
Unit of analysis issues
The earliest trial randomised 200 participants, but authors only
analysed the results for the 157 who were later confirmed to have
had an AMI (Rawles 1976). Ranchord 2012 also excluded five
participants in whom AMI was not confirmed and seven with-
drawn participants from the analysis. In the newly included trial
involving 638 participants with suspected AMI, randomised by
paramedic personnel in the ambulance, investigators excluded 50
for different reasons and assessed 588 for STEMI upon hospital ar-
rival (Stub 2015). Angiography was indicated (and performed) in
470 participants with clinical diagnosis of AMI. Physicians ruled
out STEMI in 29 participants (17 in the oxygen group and 12 in
the air) and confirmed it in only 441 patients, in whom investi-
gators measured the primary outcome (infarct size estimated by
troponin peak cTnI and CK). The other patients were excluded
from the primary analysis, but many clinical data including mor-
tality are available.
It is legitimately open for debate whether people who did not have
an AMI should be included in a study of the benefits of oxygen
in AMI. Theoretically, diagnosis may be more certain today, but
not at symptoms onset, and of course a hospital physician will
be able to more accurately diagnose AMI than paramedics in the
ambulance. On the other hand, we treat suspected MIs, and these
represent some of the people to whom a treatment would be given
in practice.
Wehave therefore performed two analyses: one in participantswho
had confirmed AMI in Rawles 1976, Ukholkina 2005, Ranchord
2012 and Stub 2015, and a second that also covered all participants
from the trials in a strict intention-to-treat (ITT) analysis that
included the 43 participants from Rawles 1976 who did not have
an AMI confirmed, the 12withdrawn participants fromRanchord
2012, and the 197 (of the 638 randomised participants) fromStub
2015 in which STEMI was ruled out. This was to preserve the
strict randomisation process and to minimise selection bias.
Dealing with missing data
We contacted study authors for missing data.
Assessment of heterogeneity
We assessed heterogeneity by visual inspection of the outcomes
tables of the different analysis and using the I2 statistic (where I2
> 50% was considered substantial or considerable heterogeneity)
(Higgins 2003).
Assessment of reporting biases
As there were only five studies that met the inclusion criteria, it
was not possible to explore reporting bias using funnel plots or the
Begg and Egger tests (Begg 1994; Egger 1997).
Data synthesis
We undertook meta-analyses where data were available and it was
clinically sensible to do so, using both fixed-effect and random-
effects models. We reported the results using both models because
we recognise that readers may have different perspectives (for ex-
ample preconceptions, values or contexts) and different people
may wish to see the results with the different mathematical as-
sumptions.
Subgroup analysis and investigation of heterogeneity
The data were too sparse to permit adequate exploration of all the
subgroups that had been pre-specified for analysis (such as timing
and duration of oxygen therapy, pre-existing levels of hypoxaemia
or othermeasures of severity of infarction).We undertook an anal-
ysis including only the trials undertaken during the reperfusion
era, as these reflect today’s clinical practice. We define ’reperfusion
era’ as the period in which thrombolysis, PCI or CABG were gen-
eralised as the main treatment for AMI (since 1985).
Sensitivity analysis
Similarly, our intention to explore the effect of trial quality in a
sensitivity analysis was limited by the number of trials and the
quality of reporting. We undertook separate analyses using the
confirmed AMI population and the ITT population, and under-
took ’best-case’ and ’worst-case’ scenarios in sensitivity analysis for
the missing data on deaths (Wilson 1997).
Summary of findings table
We created a ’Summary of findings’ table for the outcomes all-
cause mortality in hospital for participants with AMI, all-cause
mortality in hospital for all participants, all-cause mortality in hos-
pital for all participants in trials done in the revascularisation era,
opiate use as a proxy measure for pain, recurrent myocardial in-
farction, infarct size by CK and other enzymes, and infarct size
by MRI. We used the five GRADE considerations (study limita-
tions, consistency of effect, imprecision, indirectness and publica-
tion bias) to assess the quality of a body of evidence as it relates
to the studies which contribute data to the meta-analyses for the
prespecified outcomes (Guyatt 2008). We used methods and rec-
ommendations described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions using
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GRADEpro software (GRADEpro; Higgins 2011). We justified
all decisions to down- or upgrade the quality of studies using foot-
notes, and we made comments to aid readers’ understanding of
the review where necessary.
R E S U L T S
Description of studies
Results of the search
We identified 204 new records with the updated search in June
2016.The removal of duplicates left 136new records for screening.
Based on title and abstract, we excluded 111 papers and retrieved
25. Ten were reviews, editorials or non-randomised studies, three
RCTs were not relevant to our purpose, and five were references for
ongoing trials. The remaining seven records all reported one new
randomised controlled trial that was eligible for inclusion (Stub
2015): three were conference abstracts, one was the protocol, one
was the main study, and the remaining two were respectively a
sub-group study and re-analysis of the same study. We describe
the process in Figure 1.
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Figure 1. Study flow diagram with previous included studies incorporated into the results of the updated
literature search.
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Including the papers identified in the previous version of the re-
view,we retrieved a total of 2892 records and screened2442unique
records (Figure 2). Based on title and abstract, we excluded 2268
and retrieved 174 full papers retrieved. We excluded a further 162
articles, as 138 were not RCTs or were RCTs not related to our
review, 16 were excluded for various other reasons, 5 were refer-
ences for ongoing studies (NCT01787110; NCT02290080), and
3 were ongoing trials identified in the previous version of this re-
view (old ongoing trials). This left 12 papers reporting five tri-
als that met the inclusion criteria (Ranchord 2012; Rawles 1976;
Stub 2015; Ukholkina 2005; Wilson 1997). We describe the pro-
cess with reasons for exclusion in Figure 2 and the list of excluded
trials in Characteristics of excluded studies.
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Figure 2. Study flow diagram (cumulative searches)
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With respect to the three ongoing trials identified in the previous
version of this review, we included one of them in this review
(Stub 2015). The protocol of a second study has been published
as paper but the final report has not (NCT01423929). The third
protocol, identified exclusively by trials register, has not started,
and the register had reported no activity as of September 2016
(ACTRN12609000466246). We therefore maintained these two
last trials as ongoing trials in this version of the review.
In total, we identified four ongoing trials as of September 2016
(see Characteristics of ongoing studies). All four are parallel de-
signs to compare oxygen (O2) versus air in people with sus-
pected acute myocardial infarction (AMI). In the first study, the
main outcome is in-hospital mortality (this study, despite hav-
ing been registered in 2009, has not yet commenced recruitment
(ACTRN12609000466246). In the second study, the primary
outcome is infarct size estimated by magnetic resonance imaging
(MRI) and myocardial salvage index by MRI (NCT01423929);
in the third study, the main outcome is one year all-cause mor-
tality, while secondary outcomes are 30-days mortality as well
as major adverse cardiac events (MACE) at 30 days and one
year, including reinfarction and hospitalisations for cardiac fail-
ure (NCT01787110). This third study has nested a fourth trial
with a slightly different architecture and oriented exclusively to
biochemical outcomes (NCT02290080).
Included studies
The five included trials took place between 1976 and 2015
(Ranchord 2012; Rawles 1976; Stub 2015; Ukholkina 2005;
Wilson 1997). Two were conducted in the UK (Rawles 1976;
Wilson 1997), one in Russia (Ukholkina 2005), one in New
Zealand (Ranchord 2012), and one in Australia (Stub 2015).
All five studies were parallel-design, randomised controlled trials.
Rawles 1976 was double-blind, and the other four were open-la-
bel.
Population: a total of 1173 participants were involved, of whom
75.3% were men. Three studies recruited participants with sus-
pected AMI (Ranchord 2012; Rawles 1976; Stub 2015), and the
other two included only people with confirmed AMI (Ukholkina
2005; Wilson 1997). The mean ages in years (and standard errors
where given) of the included participants in each group were as
follows: Rawles 1976: air, 50.8 years (SE 2.4); O2, 51.3 years (SE
1.7); Wilson 1997: air, 64 years; O2, 65 years; Ukholkina 2005:
air, 53.5 years (SE 1.06); O2, 55.6 years (SE 1.33); Ranchord
2012: air, 60 years (SE 12.8); O2, 62.1 years (SE 12.5). In Stub
2015, themedian and interquartile range were 62 years (IQR 53.0
to 71.0) and 63.5 years (IQR 54.0 to 73.0) for the air and oxygen
groups, respectively.
Intervention: in all five included trials the interventionwas inhaled
oxygen at 4 L/min to 8 L/min. Administration was by mask in
four studies and by a nasal cannula in the other study (Ukholkina
2005). The comparator was air in four studies, breathed normally
in the two open-label studies and given at 4 L/min to 6 L/min by
facial mask in the double-blind study. In the remaining study, the
comparison was titrated oxygen delivered by nasal prongs or mask
adjusting the flow-rate to achieve an oxygen saturation of 93% to
96% (Ranchord 2012).
Outcomes: all five studies reported death. Stub 2015 explicitly
measured pain, while Rawles 1976 and Wilson 1997 reported
opiate usage (as a proxy for pain). Four studies included infarct
size estimated by electrocardiogrammapping (ECG), biochemical
markers such as creatine kinase (CK), troponin (I or T) or BNP.
Finally, two studies estimated infarct size byMRI (Ranchord 2012;
Stub 2015).
The main characteristics of the included studies are in
Characteristics of included studies.
Excluded studies
Of the 162 excluded articles, 80 did not report original data, 38
were not RCTs, 20 were RCTs of interventions that were not rel-
evant to our study; and 16 papers reported studies that had a dif-
ferent oxygen intervention (8 used hyperbaric oxygen; 6, aque-
ous oxygen; 1, oxygen associated with haemoglobin; and 1, oxy-
gen combined with nitric oxide versus placebo for pain control).
Three records were related to previously identified ongoing tri-
als. Of the five remaining papers, four were related to an ongo-
ing trial (register, protocol, and two proceedings of congress of
NCT01787110), and the other one was the protocol of a nested
ongoing trial (NCT02290080). Themain characteristics of the ex-
cluded studies are in the table Characteristics of excluded studies.
Risk of bias in included studies
Allocation
Three studies provided no description of randomisation sequence
generation (Rawles 1976; Ukholkina 2005; Wilson 1997), and
we therefore judged this domain to be at unclear risk of bias. In
Ranchord 2012, a random number sequence was generated by a
computer programme. This study was undertaken in two centres
and randomisation was not stratified by centre; nevertheless we
judged this as being at low risk of bias. In Stub 2015, a computer-
generated code into blocks of 10 was used (low risk of bias).
In four studies, allocation was concealed using numbered sealed
envelopes (Ranchord 2012; Rawles 1976; Stub 2015; Wilson
1997), so we judged them as being at low risk of bias. Ukholkina
2005 did not report the method of allocation concealment, so
we judged it as being at unclear risk of bias. In Ranchord 2012
16Oxygen therapy for acute myocardial infarction (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(two centres) there is no description of how the envelopes were
distributed to each centre, but we judged it to carry a low risk.
In Stub 2015 trial allocation concealment was accomplished with
externally numbered sealed envelopes (each block of 10). Three of
these envelopes were carried in each ambulance and were replaced
with the remainder envelops from the block. When the block
was completed, a new block of 10 envelopes was allocated to the
ambulance by the study coordinator. In terms of randomisation
this may be seen as a strata for each ambulance (we judged this as
being at low risk of bias).
Blinding
Only Rawles 1976 was double-blinded. Blinding was done by us-
ing shrouded cylinders, but there is no information about how
effective this was. Nursing staff were not aware that the record of
opiate administration would be used as a proxy measure of pain.
The use of shrouded cylinders left blinding potentially compro-
mised, so we could not rule out performance and observer bias and
judged this domain as being at unclear risk of bias. However, while
this could affect the assessment of the surrogate outcomes for pain,
it is much less likely to have affected the primary outcome of this
review, which was death (Wood 2008). We have no clear informa-
tion whether infarct size measurement (through ECG, CK, tro-
ponin I, troponin T or BNP) was done blindly. In Ranchord 2012,
the cardiologist who measured the infarct size through MRI was
blinded to treatment received by the participant and to biomarker
data. Finally in Stub 2015, there is no clear information on how
investigators measured pain, but as this trial was open label, both
patient and rater are unblinded; therefore we judged this to be at
high risk of bias. Blind observers performed measurement of MRI
offline on dedicated workstations; the statistician who analysed
the data was blinded to the allocation, and a central coordinator
blinded to treatment allocation performed the six-month clinical
follow-up.
Performance and observer biases were possible in the four un-
blinded studies, which may have affected the direct measurement
of pain in Stub 2015 and the surrogate outcome for pain inWilson
1997, so we judged this as carrying a high risk of bias. Neither
Ukholkina 2005 nor Ranchord 2012 reported this outcome. The
assessment of the primary outcome (death) and the other sec-
ondary outcome of complications such as recurrent ischaemia or
AMI, heart failure, arrhythmias and pericarditis were less likely to
be subject to significant observer bias (we judged this as being at
low risk of bias). On the other hand, the methods used for in-
farct size estimation (ECG, creatine kinase, troponin T, or MRI)
are theoretically robust to observer bias, so these measures may be
considered free of observer bias (low risk).
Incomplete outcome data
All participants were followed to discharge in Rawles 1976, but
randomisation took place before confirming the diagnosis. AMI
was not confirmed in 21.5% of participants with suspected AMI.
Although this may appear high, it is not inconsistent with diag-
nostic techniques in the 1970s. Of the 105 people randomised
to oxygen and the 95 to air, AMI was not confirmed in 25 and
18 participants, respectively. The characteristics of those in whom
AMI was not confirmed were similar in both groups, and there
were no deaths among the excluded individuals.
In Wilson 1997, it was unclear for how long participants were
followed up. The analysis excluded eight people: one death, one
stroke, four who withdrew consent and two because data were
incomplete. This is 16% of the participants, and the expected
effect on the results for the primary event was very low; the risk of
bias was therefore high, but its direction is unknown.
In Ukholkina 2005, investigators measured the outcomes for 10
days and lost no participants to follow-up. However, trials pro-
vided no explicit data about the participants who were excluded
postrandomisation because of failed revascularisation or the rela-
tive number of failed revascularisations in each group. The mis-
match between the numbers reported in the tables and the text
suggest that two participants may have been excluded from the air
group and four from the oxygen group, but we cannot be certain.
Consequently, we could not include these participants in the in-
tention-to-treat analysis, and we think there is a high risk of bias
for the outcomes we measured.
In Ranchord 2012, 12 participants were excluded after randomi-
sation (four in the experimental group and eight in the control
group). The published study did not report these participants’
outcomes, which were excluded from the analysis. The reasons
for withdrawal were: absence of formal consent (n = 5), incorrect
initial diagnosis of STEMI (n = 2 acute pericarditis and n = 3 with
normal coronary arteries), and cardiogenic shock (n = 2), which
was an exclusion criterion for the study. The group to which these
participants had been allocated was not reported.
We contacted authors to try and find out to which groups the
12 withdrawn participants had been allocated and their vital sta-
tus, so that we could include them in an intention-to-treat (ITT)
analysis. Although the authors replied, the information provided
was contradictory and of limited value. Initially we were told that
five people had been withdrawn because they did not consent and
that the other seven had not been randomised. When we enquired
further about this because it contradicted the published report, we
were told that these seven had been randomised. Of concern to
us was the fact that the distribution of their allocation to groups
subsequently provided was not consistent with the numbers in
the published trial report. The authors declined to provide the
mortality outcomes for the participants who had alternative diag-
noses, stating that ”[a]lthough they are described as ’randomised
and withdrawn’ in the manuscript, they received no study treat-
ment. For these reasonswe are firmly of the view that these subjects
should not be included in the mortality analysis.“ This failure to
appreciate the nature of ITT analysis compounded our concerns
raised by the inconsistencies in the allocation information. The
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authors felt unable to tell us the mortality status of the five par-
ticipants who did not consent on the grounds that ”if they have
not consented then we can collect no further details about them“.
While we understand that trial-specific data could not be collected
on these people,mortality can be knownby publicmethods.How-
ever, we appreciate that othersmay judge this differently. The only
information of use was that three participants who withdrew be-
cause they had normal coronary arteries were alive at the end of
the study period.
The two cases excluded from the analysis by cardiogenic shock
merit special comment. While cardiogenic shock was an exclusion
criterion of the study, it is important to recognise that this is a
dynamic clinical condition that is present on admission to hospi-
tal in only 29% of those who go on to develop this complication.
The paper does not report whether the participants had cardio-
genic shock when they arrived at the hospital or not. If cardio-
genic shock developed after randomisation but before treatment,
then the exclusion of these participants could bias the results since
people with cardiogenic shock have a higher mortality rate. This
illustrates the importance of ITT analysis.
As we were unable to include these participants in the ITT analysis
because mortality data were withheld, we undertook a sensitivity
analysis with a ’worst-case’ scenario in which we tested the robust-
ness of the current estimate by assuming that both participants
received oxygen but died.
In Stub 2015, all the participants (N = 638) were followed to hos-
pital discharge. However, as randomisation occurred in the am-
bulance, and informed consent was obtained verbally and then
provided in writing at hospital, 14 people refused to participate
in the study (6 in the oxygen arm and 8 in the air) after ran-
domisation. Data about mortality at discharge are available from
all randomised participants except those who refused to give in-
formed consent (N = 624). We contacted authors to include this
information in the analysis assuming that mortality is information
that may be known by public methods (consistent with the above-
mentioned argument).
In addition, 35 participants were excluded after randomisation for
”protocol violations“, but these violations are not specified in the
publication, and one repeated enrollment was also excluded. We
contacted authors, who informed us of these causes: non-study
hospital (n = 28), chest pain for more than 12 hours (n = 12),
oxygen given prior contact paramedics (n = 2), and hypoxaemia
before enrolment (n = 3). In total, 588 participants were assessed
for STEMI in emergency department: 470 of them were eligi-
ble for angiography, but STEMI was only confirmed in 441. The
primary analysis was performed exclusively in confirmed STEMI.
The 29 patients who underwent angiography but had other diag-
noses were excluded from the analysis (17 in the oxygen arm and
12 in the air). There is no published information about the final
diagnosis of these excluded patients. We contacted the author who
informed us of the final diagnoses in the O2 group: 5 NSTEMI,
3 pericarditis, 2 apical ballooning syndrome (takotsubo) and 6
other diagnoses; and in the air group: 2 NSTEMI, 2 pericarditis,
1 aortic dissection, 4 apical ballooning syndrome, and 3 other.
Of a total of 624 randomised participants, AMI (STEMI or
NSTEMI) was confirmed in 471. This implies that in 24.5% of
randomised patients, AMI was not confirmed. This may appear to
be a high rate of misdiagnosis in contemporary practice but could
be explained, at least partially, by initial assessment undertaken by
paramedics rather than physicians - data for ’false’ activation of
the cardiac catheter laboratory for STEMI varies, but some studies
report 28% to 36% of misdiagnoses for STEMI (Barnes 2013;
McCabe 2012), suggesting diagnosis remains a challenge in the
pre-hospital phase where exposure of paramedics to STEMI is in-
frequent. There is no specific information about mortality in the
AMI group (STEMI and NSTEMI). We contacted the authors,
and all-cause mortality in AMI (STEMI orNSTEMI) at discharge
and at six months was available and is discussed below. Regarding
six-month follow-up, 11 participants each were lost in the oxygen
group and air group.
For the analysis of primary outcome in this trial, data of the peak
troponin I were available in 200 of the 218 in the oxygen group
and in 205 of 223 participants in the air group (data were missing
in 18 participants in each group, or 8.3% and 8.7% of the total,
respectively). Data on CK is reported for 217 of 218 participants
in the oxygen arm and for 222 of 223 in the air group (0.45%
and 0.44%, respectively). The impact of these lost data on effect
estimation is probably low in the case of CK (low risk of bias) but
unknown in the case of troponin I (high risk of bias). The loss of
these data may be related to the absence of a central ’core lab’ for
enzymes in this multicentre study.This last point may also induce
some doubts about the quality control of these variables, which
are the primary outcome in the Stub 2015 trial.
There is no detailed information about missing values of the
biomarkers (cTnI and CK) that were used to elaborate the respec-
tive area under curve (AUC). The study report states that when
one or more values were missing, authors addressed it through a
strategy of trapezoidal integration with multiple imputation using
a Markov Chain-Monte Carlo simulation and sensitivity analysis.
We judged this domain to be at unclear risk of bias.
Selective reporting
Protocols were unavailable for older studies. Rawles 1976 was the
best-quality trial, and we believe that the report probably included
all the prespecified variables. InWilson 1997, the primary purpose
was to look at the incidence and degree of hypoxaemia and the
effect of oxygen on hypoxaemia, rather than this review’s primary
outcome of death; the participant who died was excluded from
the analysis. Despite contacting the authors, we were unable to
establish in which group the death occurred, and we could not
include this study in themeta-analysis. We carried out a sensitivity
analysis to assess the potential risk of bias.
In Ukholkina 2005, ECGs were mapped to estimate the surrogate
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outcome of infarct size, but only in a subset of 31 participants
in the oxygen group; there was no information for the air group.
We therefore believe that it is not possible to draw meaningful
conclusions about infarct size.We do not think the pain and death
outcomes were subject to selective reporting.
In Ranchord 2012 the infarct size, estimated by MRI, was under-
taken in a small subgroup of 71 participants (selective reporting
of subgroup). In addition, neither the protocol nor the trial report
give any defined criteria on whether or not to perform MRI, so
this analysis should be considered a non-randomised comparison.
On the other hand, given that MRI was performed four to six
weeks after AMI, this specific subgroup represents a cohort of sur-
vivors, which also needs to be taken into account in the infarct size
comparison. We judged this study to be at high risk of selective
reporting bias.
In Stub 2015, all patients ”who were agreeable to travel to a core
site for scanning“ were invited for MRI, which was therefore per-
formed in a self-selected subgroup of 139 participants: 65 in the
oxygen group and 74 in the air group (selective reporting of sub-
group).The self-selection implies that randomisation was broken
and therefore the comparison of infarct size estimated byMRI is a
non-randomised comparison, very sensitive to selection bias. On
the other hand, MRI was performed six months after the STEMI;
consequently the infarct size was estimated in a cohort of survivors.
If we accept an association between infarct size and mortality, the
comparison between oxygen and air will be biased towards the
null hypothesis. We judged this study to be at high risk of selective
reporting bias.
Other potential sources of bias
We did not identify any other biases in Rawles 1976 or Wilson
1997.
Ukholkina 2005 reported differences in infarct size between the
two interventions, but the authors did not specify the time after
symptoms onset when creatine phosphokinase M and B isoen-
zymes (MB-CPK) were measured; they were not measured at the
same time in all participants. In addition, no information was
provided about the consistency and validity of the method used
to map myocardial damage (number and blinding of observers;
reliability and repeatability of their measurements; whether there
were disagreements and, if so, how these were resolved). While
these methodological weaknesses call into question the reliability
of the estimation of myocardial damage, they do not affect the
main outcomes of this review. Only Ukholkina 2005 reported
complications, but there was an inconsistency between the data
in the table and the text. We recalculated complication rates and
used these data in our analysis.
In Ranchord 2012, prior to randomisation both the experimen-
tal and control groups received pre-hospital oxygen (86.8% and
63.0%, respectively). If the effect of oxygen truly determines the
outcome, then this pre-randomisation intervention could have
produced a bias in effect estimation toward the null hypothesis
(i.e. a reduction of the study power).
In Stub 2015, we detected some differences between the final pa-
per and the published protocol. Firstly, the study population in
the protocol is ”suspicion of STEMI“ but in the final paper the
analysis was performed in confirmed STEMI (normoxic patients
with STEMI). Secondly, there are differences in the sample size
calculations despite using similar assumptions: in the protocol the
estimated sample size was 490 (245 patients in each arm) while
in the paper the sample size calculation was 600 participants, and
638 were enrolled. Finally, the protocol reported planning an in-
terim analysis after randomisation of 100 participants in each arm,
while in the paper the interim analysis was performed after 405
participants were recruited. In both cases justification for these
number of patients to make the interim analysis is unclear, and
there is no reflection about implications for the statistical analysis.
It is difficult to know the possible impact on validity of these
discrepancies between the paper and the protocol (unclear risk
of bias). However it is clear that authors changed some decisions
regarding the conduct of the study after commencing, and they did
not adequately explain these decisions in the paper. This suggests
that some decisions could have been ’data-induced’ or motivated
by post hoc hypotheses.
Baseline characteristics
Overall, the two groups appeared similar after randomisation in
Rawles 1976 andWilson 1997. InUkholkina 2005 the two groups
appeared similar in age, smoking, hypertension, unstable angina
and cholesterol. There was a (non-significant) difference in the
Killip stage, with more Killip II in the oxygen group than in the
air group. Time to revascularisation was 41 minutes shorter in
the air group (P = 0.052), which even if due to chance may have
important clinical implications for our outcomes of interest. In
Ranchord 2012 the two groups appear similar in age, sex, body
mass index, diabetes, hyperlipidaemia, hypertension and previ-
ous coronary artery bypass grafting. There were differences in the
number of previous percutaneous coronary interventions (PCIs),
and in the infarct territory, with less anterior infarction in the ex-
perimental group than in the control group (18% versus 31%).
In Stub 2015 baseline characteristics are reported for 441 partici-
pants with STEMI confirmed by angiography. There was no clear
difference between oxygen and air regarding important clinical
characteristics. Surprisingly, there is no description of the baseline
characteristics of all randomised patients according to table 1 of
the CONSORT statement. Therefore we cannot make a judge-
ment on whether the randomisation process worked, given that is
not possible to explore the differences in potential confounding
factors between randomised groups.
Summary of risk of bias
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Death as an outcome had a low risk of bias in Rawles 1976 and
Stub 2015, was not adequately reported inWilson 1997, and had a
high risk of bias inUkholkina 2005. There are also the ’withdrawn’
participants from Ranchord 2012, for whom we had no outcome
data and do not know their vital status. We therefore consider
the overall risk of bias for mortality in the meta-analyses to be
high. For pain, we consider the risk of bias to be unclear in Rawles
1976 and high in Wilson 1997 and Stub 2015. Consequently
we consider the risk of bias in the meta-analysis for pain to be
high. For ischaemia recurrence there are low risks of bias in both
Ukholkina 2005 and Stub 2015 (Figure 3).
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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For infarct size estimated by CK andMB, there is high risk of bias
in Ukholkina 2005 and a low risk of bias in Stub 2015. For infarct
size by different troponins the risks are unclear in Ranchord 2012
and Stub 2015. Finally, for infarct size estimated by MRI there is
high risk of bias in both Ranchord 2012 and Stub 2015.
Effects of interventions
See: Summary of findings for the main comparison Oxygen
versus air for acute myocardial infarction
All-cause mortality
All five trials reported the observed mortality at hospital discharge.
Rawles 1976 found more deaths in the group randomised to oxy-
gen than in the air group, both for all randomised participants
with suspected AMI (N = 200) and for those with confirmed AMI
(N = 157). Wilson 1997 described one death but did not report
in which group it occurred. We contacted both of the authors of
the original paper, who confirmed that they no longer had the trial
data and did not remember in which arm the death and the stroke
had occurred; however, they stated that 25 participants had been
randomised into each group. In Ukholkina 2005, only 1 person
out of 58 died in the oxygen group and none out of 79 partici-
pants died in the air group. In Ranchord 2012 ,1 participant out
of 68 died in the high oxygen group and 2 out 68 in the titrated
group. Twelve participants (4 in the high oxygen group and 8 in
the titrated group) were withdrawn after randomisation, with the
mortality data for these 12 people not reported in the paper. We
contacted the authors of the trial, but they were unable to provide
the missing data for these cases. In Stub 2015 the all-cause mor-
tality at discharge was 4 out 218 and 10 out 223, respectively, for
the oxygen and air groups in confirmed STEMI, and 5 out 231
and 11 out 240 respectively for the AMI (STEMI or NSTEMI).
We could only combine results from four of the five studies
(Ranchord 2012; Rawles 1976; Stub 2015; Ukholkina 2005). In
contrast with previous versions of this review, in the meta-analysis
of the current version, the same number of people died (n = 16) in
each group . This suggests oxygen effect is not good, but not harm-
ful. The complete results are given numerically below together
with the GRADE assessment in the Summary of findings for the
main comparison (Guyatt 2008).We also present the sensitivity
analysis for the missing data from Wilson 1997 and Ranchord
2012 .
Meta-analysis for mortality in participants with confirmed AMI:
risk ratio (RR) 1.02 (95% CI 0.52 to 1.98); I2 = 49%, fixed-effect
model; 4 trials, N = 871, quality of evidence: very low (Analysis
1.1). The effect does not change when applying a random-effects
model (Analysis 1.2).
Meta-analysis for mortality in an ITT population, including those
who did not have AMI showed an RR of 0.99 (95% CI 0.50 to
1.95; I2 = 46%, fixed-effect model; 4 trials, N = 1123, quality of
evidence very low; Analysis 1.3). The effect does not change when
applying a random-effects model (Analysis 1.4).
Sensitivity analysis formissing information about the arm inwhich
the death occurred in Wilson 1997 (ITT analysis): a ’worst-case’
scenario assuming that the participant who died was in the oxygen
arm gave an RR for death of 1.05 (95%CI 0.54 to 2.02; I2 = 33%;
fixed-effect model; 5 trials, N = 1173; Analysis 1.5). A ’best-case’
scenario assuming that the participant who died was in the air arm
gave an RR for death of 0.94 (95% CI 0.49 to 1.80; I2 = 32%;
5 trials, N = 1173; Analysis 1.6). In both cases we used a fixed-
effect model. Sensitivity analysis for missing information about
the group in which the two participants of Ranchord 2012 with
cardiogenic shock were allocated: assuming that both participants
died, a ’worst-case’ scenario in which both were in the oxygen arm
gave an RR of 1.11 (95% CI 0.58 to 2.15; I2 = 45%; 4 trials, N =
1123; Analysis 1.7) and a ’best-case’ assuming that the participants
were in the control arm gave a RR of 0.89 (95% CI 0.046 to 1.71;
I2=54%; 4 trials, N = 1123; Analysis 1.8).
The subgroup analysis, including only the three most recent trials,
all whichwere performed in the reperfusion era (Analysis 1.9), gave
an RR for death of 0.58 (95%CI 0.24 to 1.39; I2 = 0% fixed-effect
model; 3 trials, N = 923, quality of evidence: low). Despite being
recent, two of these three studies did not meet current standards
of trial design and conduct and are at high risk of bias (see Risk of
bias in included studies).
Only Stub 2015 reported all-cause mortality at six months: 9 par-
ticipants out 318 died in oxygen group versus 13 out 320 in the
air group (RR 0.39, 95% IC 0.14 to 1.07; 1 trial, N = 628).
Cardiac mortality
Only Stub 2015 reported cardiac mortality, with 4 out 318 and 7
out 320 participants dying in the oxygen and air groups, respec-
tively (RR 0.58, 95% CI 0.17 to 1.95; 1 trial, N = 628).
Cardiac failure
Two studies reported cardiac failure (Rawles 1976; Wilson 1997).
In Ranchord 2012, cardiogenic shock was an exclusion criterion
for the study, so the two cases that occurred postrandomisation
were excluded from the analysis. In Ukholkina 2005, cardiogenic
shock and cardiac failure at hospital arrival were also considered
criteria for exclusion from the trial. In included participants, car-
diac failure was reported in one and five participants in the oxygen
and air groups, respectively. In Stub 2015, 20 participants in each
group presented cardiogenic shock. The meta-analysis for cardiac
failure showed no significant difference between groups (RR 0.88,
95% CI 0.50 to 1.55; I2 = 27%, 2 trials, N = 775; Analysis 1.10).
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Stroke
Only one trial reported stroke or transitory ischaemic attack,which
occurred in 3 out 218 participants in the oxygen group and and
1 out 223 in the air group (Stub 2015).
Recurrence of myocardial infarction or ischaemia
Recurrence of ischaemia was similar in both groups in Ukholkina
2005: it occurred in 12 participants in the oxygen group (N=58)
and 16 (N= 79) in the air group (RR 1.02, 95%CI 0.52 to 1.99; 1
trial, N = 137). Conversely in Stub 2015, recurrence of myocardial
infarction or ischaemia at hospital discharge occurred in 12 out
218 participants in the oxygen group and in 2 out 223 in the air
group (RR 6.14, 95% CI 1.39 to 27.1), which suggests a negative
effect for oxygen. The effect estimate from both studies suggests a
disadvantage for oxygen, but this is not significant: meta-analysis
of the two trials shows an RR of 1.67 (95% CI 0.94 to 2.99; I2=
80%, 2 trials, N = 578, quality of evidence: low; Analysis 1.11).
This substantial heterogeneity could be due to different causes.
In Ukholkina 2005, inclusion criteria were uncomplicated AMI,
exclusion criteria included cardiogenic shock, and failure in revas-
cularisation was considered cause for study withdrawal. Moreover,
the study setting was clearly different: participants in Ukholkina
2005 were recruited in hospital, versus pre-hospital in Stub 2015
(methodological sources of heterogeneity). On the other hand,
part of the observed heterogeneity may be related to technologi-
cal and procedural advances in percutaneous intervention (stent-
ing, thromboaspiration, etc.) and with progress in the use of adju-
vant antiplatelet medication in the decade separating the two tri-
als (clinical sources of heterogeneity). Finally, some heterogeneity
may be statistical.
Recurrence of myocardial infarction at six months in Stub 2015
occurred in 16 (out 218) and8 (out 223) participants in the oxygen
and air groups respectively (RR 2.05 [95% CI 0.89 to 4.68] 1
trial, N=441)
Major bleeding
Stub 2015 was the only trial to report major bleeding: 9 and 6
cases were reported in the oxygen (n = 218) and air groups (n =
223), respectively (RR 1.53, 95% CI 0.56 to 4.24, 1 trial, N =
441). In two cases in the air group, this outcome was the cause of
death.
Pain
Stub 2015 directly measured pain at two time points: on arrival
of paramedics and on arrival at hospital. The median pain scores
were exactly the same for both the oxygen and air groups in both
measurements: median 6.0 (IQR 4.8 to 8.0) versus 6.0 (IQR 4.0
to 8.0) on arrival of paramedics, and 2.0 (IQR 0.0 to 4.0) ver-
sus 2.0 (IQR 0.5 to 3.5) on arrival at hospital.There is not ex-
plicit description of the used tool for this measurement (probably
a 10-point VAS scale). In two other studies, the authors reported
diamorphine use as a proxy for pain: in Rawles 1976, a similar
proportion of participants from both groups received analgesia.
The total dosage was similar: 54.3% of randomised participants
(71.3% of those with confirmed AMI) in the oxygen group re-
ceived analgesia, with an average of 2.1 doses (standard deviation
(SD) 1.5), but it was not clear whether the denominator was par-
ticipants who used diamorphine or all participants; 54.7% of ran-
domised participants (67.5% of those with confirmed AMI) in the
air group received analgesia, with an average of 2.0 doses (SD 1.4),
but again the denominator population was not clearly defined. In
Wilson 1997, the authors reported opiate use as a proxy for pain.
Although 50 people were randomised, authors reported results for
just 42, as follows: 16 of 22 participants (72.7%) in the oxygen
group used opiates; 18 of 20 participants (90%) in the air group
used opiates. Ukholkina 2005 did not measure pain or opiates
use.Thus, we can only combine results from two studies (Rawles
1976; Wilson 1997), which showed no difference in opiate use
between the oxygen and the air groups. Meta-analysis for opiate
use in confirmed AMI showed the following results (fixed-effect
model): RR 0.99 (95% CI 0.83 to 1.18; I2 = 54%, 2 trials, N =
190, quality of evidence: low; Analysis 1.12). Applying a random-
effects model slightly altered these results: RR 0.94 (95% CI 0.72
to 1.23; I2 = 54%, 2 trials, N = 190; Analysis 1.13). Meta-analysis
for opiate use in the ITT population including those who did not
have an AMI (fixed-effect model): RR 0.97 (95%CI 0.78 to 1.20;
I2 = 0%, 2 trials, N = 250, quality of evidence: low; Analysis 1.14).
This remained unchanged using a random-effects model: RR 1.04
(95% CI 0.78 to 1.38; I2 = 0%; Analysis 1.15).
Revascularisation
Revascularisation (as the current standard of the treatment inAMI)
was a criteria for inclusion in the threemost recent trials (Ranchord
2012; Stub 2015; Ukholkina 2005). Only Stub 2015 reported
’new’ revascularisation as an outcome. Twenty-three of 218 partic-
ipants in oxygen group and 16 of 223 in the air group underwent
revascularisation. There is no information about the causes of new
revascularisation nor of the techniques used for it.
Pericarditis
Only Ukholkina 2005 reported pericarditis as a complication of
AMI: 1 participant in the oxygen group (n = 58) and 6 partici-
pants in the air group (n = 79) experienced this outcome. Stub
2015 randomised and included 15 cases of acute pericarditis in
the study as AMI (9 in the oxygen and 6 in the air group). The
true diagnosis was made after catheterisation, leading to these par-
ticipants’ exclusion from the study analysis. However, we have in-
cluded these participants in the ITT analysis.
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Arrhythmia
Four trials reported different types of arrhythmias, but the in-
formation is not detailed enough to make a qualitative syntheses
(Rawles 1976; Stub 2015; Ukholkina 2005; Wilson 1997).
Left ventricular function
Three studies estimated ventricular function using different imag-
ing techniques (echocardiography, MRI) (Ranchord 2012; Stub
2015;Ukholkina 2005). Investigators performedmeasurements at
different points of AMI clinical evolution, and given the dynamic
condition of this outcome in AMI, the variability in considered
time points may be an important source of variability in the re-
sults. Thus, we did not attempt any synthesis for this outcome.
Infarct size estimation
Four of the five studies explored the effect of oxygen on infarct
size using different methods (Ranchord 2012; Rawles 1976; Stub
2015; Ukholkina 2005).
In the oldest trial (Rawles 1976), investigators estimated infarct
size by means of maximum serum aspartate aminotransferase lev-
els. In two other studies, authors used CK or CK-MB (peak or
AUC): in Ukholkina 2005, CPK and MB-CPK activity was sig-
nificantly higher in the oxygen arm at 6 hours and 24 hours of
symptoms onset, while at other time points of the clinical evolu-
tion (between 12 and 18 hours, as well as at 36 and 48 hours after
onset) the levels of MB-CPK and CPK were significantly lower
in the oxygen group. The authors considered this ambiguous re-
sult to be favourable to oxygen but provided no coherent expla-
nation for these data. Stub 2015 found a significant increase in
the geometric mean peak of creatine kinase in the oxygen group
compared with the non-oxygen group (1948 U/L versus 1543 U/
L; geometric means ratio 1.27, 95% CI 1.04 to 1.52). There was
a similar result when using the AUC: ratio of geometric means
of AUC 1.19 (95% CI 1.01 to 1.40). Given the huge differences
in the timing of blood sampling, in laboratory methods and in
mathematical expression, it was not possible to make quantitative
syntheses of infarct size by CK. On the other hand, the two more
recent trials measured different subtypes of troponin. In Ranchord
2012, the mean ratio of troponin T in the oxygen versus air group
was 0.74 (95% CI 0.50 to 1.10), and in Stub 2015, the mean
ratio of troponin I between oxygen and air was 1.20 (95% CI 0.92
to 1.56); no significant differences were apparent in either case.
It was not possible to undertake meta-analysis of infarct size by
troponin. The quality of evidence for this outcome was low.
In two studies, MRI was used to estimate infarct size (Ranchord
2012; Stub 2015). In Ranchord 2012, the mean infarct size was
15.6 g (SD 15.6) in the oxygen group and 16.3 g (SD 11.7) in the
air group. Themean difference of infarctmass between oxygen and
air groups was−0.8 g (95% CI−7.6 to 6.1). When expressed as a
percentage of left ventricular mass, mean infarct mass was 12.5% (
SD 10.9) in oxygen versus 13.1% (SD 9.7) in the air group, which
suggests a positive (but not significant) effect for oxygen. However,
in Stub 2015 the geometric mean of infarct mass was 14.6 g (IQR
11.3 to 18.3) in the oxygen group versus 10.2 g (IQR 7.7 to
13.4) in the air group, and the ratio of geometric means of infarct
size was 1.43 (95% CI 0.99 to 2.07), which suggests an increase
of infarct size in the oxygen group on the border of statistical
significance. When expressed as a percentage of infarct mass, the
geometric mean was 12.6% (IQR6.7 to 19.2) in the oxygen group
and 9.0% (IQR 4.1 to 16.3) in the air group. It is clear that
these indices have differentmathematical properties (we contacted
authors). Nevertheless, considering that these comparisons come
frombiased subgroups of patients of the trials, we considered them
unsuitable to make quantitative synthesis of infarct size estimated
by MRI. The quality of evidence for this outcome is very low.
D I S C U S S I O N
Summary of main results
We identified five studies meeting our inclusion criteria, involving
a total of 1173 participants, 32 of whom died. The quality of
the evidence, according to GRADE, ranged from low to very low
(Guyatt 2008). There were a similar number of deaths in people
receiving oxygen versus air, so for all-cause mortality at hospital
discharge there is neither evidence of benefit nor harm for oxygen
treatment in patients with AMI. This finding is consistent in the
intention-to-treat meta-analysis and the confirmed AMI meta-
analysis. Interestingly, the inclusion of the recent Stub 2015 trial
changed the RR from our previous review, where the ITT analysis
gave an RR of 2.05 (95% CI 0.75 to 5.58), compared to 0.99
(95% CI 0.50 to 1.95) in the present review. In confirmed AMI,
the RR changed from 2.11 (CI 0.78 to 5.68) to 1.02 (CI 0.52 to
1.98).
Regarding pain, there was no effect for oxygen on pain relief when
pain was directly measured nor when trials measured opiate use
as a surrogate for pain. With regard to complications following
AMI, there was no clear effect for oxygen on a range of complica-
tions, except for recurrent ischaemia, which was higher (but not
significantly so) in the oxygen group compared to the air group.
Based on outcomes that were ’important but not critical for deci-
sion-making’, particularly infarct size, there was partial evidence
that oxygen may increase infarct size as estimated by CK. How-
ever, this evidence is not consistent with CK in other trials and is
also inconsistent when infarct size is estimated through troponin
I or T (even when CK and troponin I were measured in the same
trial). Finally, there is no evidence of effect for oxygen on infarct
size as estimated by MRI.
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Overall completeness and applicability of
evidence
Regarding the applicability of the evidence, three aspects are worth
noting.
Firstly, Rawles 1976 took place before the reperfusion era (primary
percutaneous coronary intervention (PPCI) or thrombolysis) and
also before the routine use of treatments such as beta-blockers,
aspirin, angiotensin-converting enzyme inhibitors or modern an-
tiplatelet therapies, so their results may have been different in to-
day’s context. The sensitivity analysis for death in the reperfusion
era trials gave moderate quality of evidence; nevertheless, readers
should consider the resulting risk ratio (RR) of 0.58 (95%CI 0.24
to 1.39; I2 = 0%; 3 studies, N = 913) when planning future studies
(for example, in calculating sample sizes).
Moreover, the reported case fatality rates from AMI have fallen in
recent decades (Koopman 2013; Schmidt 2012; Smolina 2012;
Yeh 2010). In the studies included in this review, hospital mortality
among control participants was only 3.8%. This rate is lower than
that observed in routine surveillance data (Babaev 2005;Movahed
2009), and it is half that of the recent Euro Heart Survey in 47
countries, where hospital mortality was 6.2% (Puymirat 2013).
A possible explanation is that these trials only recruited lower-
risk participants, but it there could have also been a chance deficit
of deaths in the control arm, which would have contributed to
the apparent difference between the oxygen and control groups.
This aspect should inform participant selection criteria in future
studies.
The the most recent trial had a large impact on our estimation
of all-cause mortality. However, all cases of non-cardiac mortality
were in the air group (3 out 11: 27%), and three deaths were due
to complications presumably unrelated to oxygen: major bleeding
in two cases and sepsis in the other. In a sensitivity analysis, if
these 3 cases had occurred in the oxygen group, the RR for the
ITT meta analysis would have been 1.43 (95% CI 0.72 to 2.84),
instead of 0.99 (95% CI 0.50 to 1.95). Similar change is apparent
in the subgroup of participants in the reperfusion era: from RR
0.58 (95% CI 0.24 to 1.39) to RR 1.04 (95% CI 0.45 to 2.41).
Secondly, despite the longstanding beliefs of health professionals,
there is no evidence that oxygen has a beneficial effect on pain,
whethermeasured directly or by proxy variables. This result is con-
sistent with a new trial undertaken with oxygen versus air during
percutaneous coronary intervention for balloon-induced angina
(Zughaft 2013), which we considered but excluded from this re-
view.
A further issue to consider when assessing the contemporary rele-
vance and applicability of the earlier studies in our review is that
the definition of AMI has evolved over the years to reflect increas-
ing understanding of underlying pathophysiological processes as
well as developments in diagnostic techniques such as the high
sensitivity troponins. Furthermore, there is now recognition that
acute coronary syndromes represent a spectrum of pathophysio-
logical processes rather than a uniform type of ’heart attack’. No-
tably, there are now separate guidelines for STEMI and NSTEMI
presentations, reflecting the different therapeutic options. Future
studies should consider this spectrum of ACS, as mortality varies
by phenotype (at least in the hospital stay), but in clinical terms
the common scenario for decision-making about oxygen admin-
istration is at the point where AMI is suspected, regardless of final
diagnosis following biomarker of coronary angiography.
Bearing these considerations in mind, future studies of oxygen
in (suspected) AMI should enrol participants in the pre-hospital
phase. Given the challenges of pre-hospital diagnosis, this proba-
bly implies (as in Stub 2015) that trials will recruit a significant
proportion of participants without a subsequent confirmed diag-
nosis of AMI. To minimise this problem, some ongoing trials are
using wireless ECG transmission with interpretation by cardiol-
ogy staff and additional discussion of the patient. In any case, for
mortality and some other variables, it is possible to make a true
intention-to-treat (ITT) analysis, but assessing other clinical out-
comes such as infarct size or complications may not be practical
or appropriate for all randomised patients. The optimal time for
estimating infarct size for clinical research using MRI is worthy of
special consideration.
Quality of the evidence
The (published and unpublished) evidence in support of such a
widespread practice is surprisingly scant and scattered. We used
the GRADE approach to assess the quality of evidence and the
GRADE profiler (GRADEpro) to import data from RevMan
to create ’Summary of findings’ tables (GRADEpro; RevMan
2014).The quality of evidence for the outcomes judged critical
for decision-making was very low for death and low for pain and
for recurrent ischaemia. Therefore, with regard to these outcomes,
readers should interpret results with caution (Summary of findings
for the main comparison).
Oxygen trials have rarely investigated - and poorly reported - dif-
ferent complications such as cardiac failure, bleeding, stroke, re-
currence of ischaemia, pericarditis, etc. Despite being hard vari-
ables that are robust to observed bias, these outcomes are not to-
tally free of performance bias, and quality of the evidence is low
or very low, meriting caution upon interpretation.
Finally, for other outcomes judged ’important but not critical for
decision-making’, such as infarct sizemeasured by biologicalmark-
ers, the quality of evidence is low, and very low in the case of infarct
size estimated by MRI.
Potential biases in the review process
We were unable to determine if there was any publication bias
using formal methods, as we found only five studies for inclusion.
We cannot rule out the possibility that there are unpublished or
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ongoing studies, especially in languages other than English, that
were not indexed in the electronic databases we searched.
Regarding heterogeneity, in the meta-analysis for opiate use in
confirmed AMI, we found moderate heterogeneity (I2 = 54%),
which disappeared in the ITT analysis. While the two studies used
in the meta-analysis had differences in their design (for example,
blinded versus open-label) and attrition rates (much higher in
Wilson 1997), it was not possible to investigate the heterogeneity
further with only two trials.
Agreements and disagreements with other
studies or reviews
The findings of our updated review are not consistent with prior
reviews (Cabello 2010; Cabello 2013), and the inclusion of a new
trial has altered the evidence (point estimate) of the previous ver-
sion of this review, which suggested an excess of mortality in the
oxygen group compared to air (Stub 2015). Nevertheless, the re-
sults of this updated review are too imprecise to definitively deter-
mine whether oxygen is helpful or harmful in AMI.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence available about the effect of the oxygen on all-cause
mortality in patients with AMI is inconclusive, and we cannot rule
out a possible harmful effect. This lack of evidence is consistent
across different outcomes critical for clinical decisions. However,
the evidence in this area is sparse, of low or very low quality, and
partially predates the advances in reperfusion techniques and trial
methods of recent years. Finally, the evidence about the effects of
oxygen on other type 2 outcomes such as infarct size (estimated
through different methods) is also inconsistent and of very low
quality.
Therefore, current evidence neither supports nor clearly refutes
the routine use of oxygen in people with AMI. The implication
for clinical practice is that pending new evidence, practitioners
should only give oxygen to patients with suspected or confirmed
AMI with a blood oxygen saturation < 90% or in cases of patients
with respiratory distress.
Implications for research
As early as 1950, studies demonstrated that the administration of
pure oxygen via a facial mask not only failed to reduce the duration
of angina pain but also prolonged the electrocardiographic changes
indicative of an AMI (Russek 1950). In 1975, other authors ex-
plicitly called for further research on the topic (Salzman 1975).
Given that Rawles 1976 subsequently suggested possible harm, it
is surprising that no research groups have undertaken a definitive
study to rule out the possibility that oxygen may do more harm
than good. The recently published Stub 2015 has reactivated clin-
ical and scientific interest in the possible harmful effects of oxygen
(Nedeljkovic 2015).
Part of the reason for the failure to fund such an essential study un-
til recently may be the strong assumption (Cabello 2009; Danchin
2009), based on pathophysiological reasoning, that oxygen ad-
ministration reduces both the oxygen deficit in ischaemic myocar-
dial tissue and consequent tissue death. Indeed, both the medical
profession and the public have become so familiar with the use of
oxygen that the general attitude may have been that even if oxy-
gen does no good, it is at least not harmful. However, recent years
have seen the recognition of oxygen as a ’vasoactive substance’
(Farquhar 2009). In summary, while there are pathophysiological
reasons to believe that oxygen may have the potential to reduce
tissue damage, it is also biologically plausible that oxygen is doing
harm (see Why it is important to do this review).
Given the widespread use of oxygen for AMI, the inconsistencies
in recommendations about when and to whom it should be given,
and the fact that the best current evidence is not conclusive re-
garding benefit or harm, we maintain the belief expressed in our
previous reviews that there is an urgent need for an adequately
powered randomised controlled trial to establish the effects of ad-
ministering oxygen to people with AMI. That trial must incorpo-
rate contemporary standards in design, conduct, analysis and re-
porting of trials and address the spectrum, population and sample
size mentioned above to reflect contemporary diagnosis and care
of the patient with AMI.
Three of the identified ongoing trials are currently recruiting
participants (NCT01787110; NCT02290080; NCT01423929).
The first is an ambitious trial (DETOX-AMI) based on the na-
tional AMI registry in Sweden, focused on mortality and recruit-
ing in the pre-hospital phase of AMI, with a planned sample size
of 6000 participants. This trial has a nested sub-study focused on
biological markers. A third nested study is focused on the effect
of oxygen on infarct size estimated by biochemical markers and
MRI in patients with STEMI. The MRI study will be performed
at two to six days of AMI to determine the myocardium at risk
and to calculate the myocardial salvage index (MSI) by PCI.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ranchord 2012
Methods Open-label randomised controlled trial (6 weeks)
Participants People with ischaemic symptoms + ST-segment elevation (0.1 mV) in 2 contiguous
leads STEMI or elevation (0.2 mV) in more than 2 precordial leads (STEMI), or with
ischaemic symptoms + new onset left bundle branch block
N randomised = 148. N analysed = 136. Dropouts: withdrew consent (n = 5), alternative
diagnosis (n = 5): 2 cases with pericarditis and 3 cases with normal coronary arteries. 2
cases of cardiogenic shock (an exclusion criterion)
Mean age (SD): oxygen 60 years (12.5), air 60 years (12.8).
Sex: 77.9% men in oxygen and 70.6% men in air group
Interventions Intervention: oxygen high flow 6 L/min by concentration mask
Comparator: oxygen titrated delivered by nasal prongs or mask adjusting the flow-rate
to achieve an oxygen saturation of 93%-96%
Outcomes 30 days mortality, complications, infarct size estimated by troponin T level measured 66
h to 78 h after randomisation, infarct mass (absolute and as percentage) documented by
MRI (measured at 4-6 weeks after AMI in a subset of participants), pro-BNP measured
24 h after randomisation. As composite variable,major cardiac event (death, reinfarction,
target vessel revascularisation) at 30 days
Exclusions Previous myocardial infarction, COPD, type II respiratory failure, cardiogenic shock,
oxygen desaturation below 85%, pregnancy, bleomycin treatment or participation in
another trial
Length of follow-up 30 days for mortality, troponin T and BNP, 4-5 weeks after AMI for MRI
Clinical Context and parallel care The study was undertaken exclusively in inpatients, therefore the pre-hospital phase of
AMI was not considered
Primary percutaneous coronary intervention (PPCI) was the first-choice treatment in
one centre, while in the other, PPCI or thrombolysis was the treatment, depending on
the hour of hospital admission
Notes The study was conducted in two centres.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The sequence was undertaken by a com-
puter programme.
Allocation concealment (selection bias) Low risk Sealed envelopes
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Ranchord 2012 (Continued)
Blinding (performance bias and detection
bias)
Death
Low risk There is no threat for this outcome
Blinding (performance bias and detection
bias)
Pain (or surrogate)
Unclear risk Not applicable in this trial
Blinding (performance bias and detection
bias)
infarct size ECG
Unclear risk Not applicable in this trial
Incomplete outcome data (attrition bias)
Death
High risk There are 12 postrandomisation exclusions
for which there are no 30-day mortality
data reported
Incomplete outcome data (attrition bias)
Infacrt size (Biochemical methods)
High risk There are 12 postrandomisation exclusions
in which there are no reported biochemical
data
Incomplete outcome data (attrition bias)
infarct size ECG mapping
Unclear risk Not applicable in this trial
Incomplete outcome data (attrition bias)
Infarct size (MRI)
High risk By definition, the primary outcome (30
days mortality) implies that MRI was not
performed (by protocol performed 4-5
weeks after AMI). Data therefore not avail-
able
Selective reporting (reporting bias) High risk MRI was performed only in a subgroup
of participants (selective reporting of sub-
group)
Other bias High risk Pre-randomisation oxygen was adminis-
tered in experimental and control group
(86.8% and 63% respectively). This pre-
randomisation intervention may have pro-
duced a bias in effect estimation towards
the null hypothesis
The comparison of infarct size measured
by MRI between the two groups should be
considered a non-randomised comparison,
therefore prone to the bias of observational
studies
Baseline characteristics Unclear risk Therewere differences in previous PCI, and
in the infarct territory: anterior infarction
was less frequent in the experimental group
(18%) than in the control group (31%)
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Rawles 1976
Methods Double-blind, randomised controlled trial (In-Hospital period)
Participants People with suspected AMI presenting within 24 h of symptoms onset
Clinical setting: single site coronary care unit in the UK
N randomised = 200: 105 oxygen and 95 air. N analysed: 80 oxygen and 77 air
Excluded (non-confirmed AMI): 25 oxygen and 18 air
Mean age (SD): oxygen 51.3 years (1.7), air 50.8 years (2.4)
Sex: 60% men in oxygen and 64% in air group
Interventions Oxygen or compressed air administered by MC mask at 6 L/min over 24 h
Comparator: air at normal pressure given at 6 L/min by MC mask
Outcomes Death in Hospital, arrhythmias in 24 hours, use of opiates, maximum serum aspartate
aminotransferase levels, length of stay, systolic ejection time, hypoxaemia (first day)
Exclusions People with heart failure, bronchitis, emphysema, or other respiratory problems
Length of follow-up Discharge
Clinical Context and parallel care Prethrombolysis period
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk There was no description of how the se-
quence was generated
Allocation concealment (selection bias) Low risk Numbered sealed envelopes
Blinding (performance bias and detection
bias)
Death
Low risk Double-blinded using shrouded cylinders
(but likely that the blinding could have
been compromised)
Blinding (performance bias and detection
bias)
Pain (or surrogate)
Unclear risk Double-blinded using shrouded cylinders
(but likely that the blinding could have
been compromised, and this may affect the
assessment of this outcome: pain or surro-
gate)
Blinding (performance bias and detection
bias)
infarct size ECG
Unclear risk Not applicable in this trial
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Rawles 1976 (Continued)
Incomplete outcome data (attrition bias)
Death
Low risk There were postrandomisation exclusions
due to unconfirmed AMI (19% air group
and 24% O2 group)
Incomplete outcome data (attrition bias)
Infacrt size (Biochemical methods)
Unclear risk Not applicable in this trial
Incomplete outcome data (attrition bias)
infarct size ECG mapping
Unclear risk Not applicable in this trial
Incomplete outcome data (attrition bias)
Infarct size (MRI)
Unclear risk Not applicable in this trial
Selective reporting (reporting bias) Unclear risk There was no protocol published, but we
judged that there was no bias in reporting
the primary outcome
Other bias Low risk We did not identify other biases.
Baseline characteristics Low risk Consecutive participants, similar age, sex
Stub 2015
Methods Multicentre, open-label, randomised controlled trial (6 months)
Participants Patients ≥18 year old with ischaemic symptoms of < 12 h duration, with evidence of
STEMI defined by ST elevation > 0.1 mm in 2 contiguous limb leads, > 0.2 mm in 2
contiguous chest leads, or new left bundle branch block. In the published protocol the
participants were defined as those with suspected STEMI. The recruitment was made
in the pre-hospital setting (by paramedics in the ambulance) and the informed consent
was obtained after the arrival at hospital (delayed consent)
N randomised = 638. N analysed = 441: 14 refused consent, 35 exclusions for protocol
violations, 1 repeated enrollment (see text). Elegible for angiography: 470 (471 for
authors), 29 other diagnosis
Mean age (SD): oxygen 13.0 years ( 11.9), air 62.6 years (13.0)
Sex: 79.8% men in oxygen, 78.0% men in air group
Interventions Intervention: oxygen by mask 8 L/min
Comparator: air
If the oxygen saturation fell below94% then titrated oxygenwas administered by cannula
or face mask to achieve an oxygen saturation of 94%
Outcomes Infarct size estimated by cTnl and CK (in both cases geometric mean peak and geometric
mean of AUC) at 72 h of reperfusion
Pain score (measured on arrival of paramedics and on arrival at hospital). The scale for
measuring pain is not described in the protocol nor in the paper
Survival at hospital discharge, mortality andmajor adverse cardiac events (MACE: death,
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Stub 2015 (Continued)
recurrent myocardial infarction, repeat revascularisation, and stroke) were assessed at 6
months
Infarct size was estimated by MRI at 6 months after hospital discharge. An MRI was
undertaken in a subset of self-selected participants (non-random comparison)
*All primary efficacy and safety outcomes (mortality , cardiac arrest and unplanned
intubation) were explored by a monitoring committee in an interim analysis made after
450 randomisations. In the protocol this interim analysis was planned after 100 were
randomised to each arm. This planned analysis is not reported, and no adjustments for
multiple comparisons were undertaken
Exclusions Oxygen desaturation < 94% (pulse oximeter); bronchospasm requiring salbutamol neb-
ulised; altered conscious state; oxygen administration prior to randomisation
Length of follow-up 6 months
Clinical Context and parallel care Primary percutaneous coronary intervention (PPCI) was the first-choice treatment in
all the participant hospitals. All the patients received aspirin 300 mg in ambulance and
antiplatelet therapy according to interventional cardiologist criteria
Notes This was a multicentre study undertaken in 9 metropolitan hospitals that provide 24 h
percutaneous coronary intervention services
The participant were included, randomised and treated (with oxygen or air) before the
arrival at hospital (in the ambulance), and therefore the trial was designed to cover the
pre-hospital phase of STEMI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The sequence was computer-generated
code in blocks of ten.
Allocation concealment (selection bias) Low risk Sealed envelopes in each ambulance par-
ticipating in the study: 3 envelopes of the
block of 10, and replaced with other of the
block, and after new block by coordinator.
??
Blinding (performance bias and detection
bias)
Death
Low risk There was no information in the paper
about participants who refuse to give in-
formed consent and we contacted the au-
thors for more information
Blinding (performance bias and detection
bias)
Pain (or surrogate)
High risk This was an open label trial, although pain
scores are shown, there is no description of
the scale and methods used to measure the
pain
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Stub 2015 (Continued)
Blinding (performance bias and detection
bias)
infarct size ECG
Unclear risk Not applicable in this trial
Incomplete outcome data (attrition bias)
Death
Low risk Mortality at discharge and six month fol-
lowing the patient’s randomisation
Incomplete outcome data (attrition bias)
Infacrt size (Biochemical methods)
High risk Peak of creatin kinase is reported in 217 of
218 participants in oxygen arm and in 222
of 223 in the air (loss of 0.45% and 0.44%
respectively). Low risk of bias
Peak of troponin I is reported in 200 of the
218 in the oxygen group and 205 of 223
participants in the air (loss of 8.3% and 8.
7% respectively). High risk of bias
The missing values in serial enzyme esti-
mation to built the AUC are unknown (a
method is described as a Markov method
was used to performed the estimation of
AUC. Unclear risk of bias
Incomplete outcome data (attrition bias)
infarct size ECG mapping
Unclear risk Not applicable in this trial
Incomplete outcome data (attrition bias)
Infarct size (MRI)
High risk The MRI was done in a self-selected group
of study population, this implies the exis-
tence of high risk of selection bias and the
nullification of the balancing effect of ran-
domisation
Selective reporting (reporting bias) High risk MRI was performed only in a subgroup of
’self-selected’ participants (selective report-
ing of subgroup)
In addition, the MRI was undertaken 6
months after the STEMI and the popula-
tion represents a cohort of survivors
Other bias Unclear risk Protocol deviation, sample size, interim
analysis
Baseline characteristics Unclear risk There is a table with the description of
key data in both groups with confirmed
STEMI, but there is no table comparing the
baseline characteristics of all randomised
patients (table 1 of CONSORT)
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Ukholkina 2005
Methods Randomised, open-label, controlled trial (10 days)
Participants Confirmed AMI within 12 h of onset of symptoms.
Clinical setting: single-site coronary care unit in Russia
N randomised = 137. No explicit data were provided about the participants who were
excluded postrandomisation
Mean age (SD): oxygen 55.6 years (1.33), air 53.5 years (1.06)
Sex: 45% men in oxygen and 70% in air group
Interventions Oxygen for 3 h after intervention administered via nasal cannulae 3-6 L/min (FiO2 30%-
40%) and 30 min before the PCA in a subgroup of 30 participants
Comparator: air
Outcomes Death, arrhythmias within 1 h of reperfusion, surgery during hospital stay, recurrent
AMI, postinfarction angina, hypoxaemia, heart failure, pericarditis
Area of tissue damage measured by ECG mapping and cardiac enzymes (CK-MB)
Exclusions People with complicated AMI, congestive heart failure, pulmonary disease, COPD or
anaemia
Length of follow-up 10 days
Clinical Context and parallel care Context of primary PCI
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Death
Low risk This was an open-label trial (but absence of
blinding unlikely to introduces bias in this
outcome)
Blinding (performance bias and detection
bias)
Pain (or surrogate)
Unclear risk Not applicable in this trial (pain was not a
variable evaluated in the study)
Blinding (performance bias and detection
bias)
infarct size ECG
Unclear risk This was an open-label trial (but the ab-
sence of blinding unlikely to introduce bias
in this outcome)
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Ukholkina 2005 (Continued)
Incomplete outcome data (attrition bias)
Death
High risk While mortality was adequately reported
for included participants, there was inad-
equate description of exclusion postran-
domisation in each group (e.g. failed revas-
cularisation)
Incomplete outcome data (attrition bias)
Infacrt size (Biochemical methods)
High risk There was inadequate description of exclu-
sion postrandomisation in each group
Incomplete outcome data (attrition bias)
infarct size ECG mapping
Unclear risk Inadequate description of exclusion pos-
trandomisation in each group (e.g. failed
revascularisation). Consequently, these
participants are not included in the infarct
size comparison. There were problems of
consistency in the measurement process of
ECGmapping done to estimate infarct size
Incomplete outcome data (attrition bias)
Infarct size (MRI)
Unclear risk Not applicable in this trial
Selective reporting (reporting bias) High risk We have no information about the proto-
col, but the infarct size estimation was only
reported in 31 patients in the oxygen group
and no information in the air group
Other bias High risk See baseline imbalances
Baseline characteristics High risk The groupswere different at baseline in two
important variables:
1. Clinical class Killip and Kimball
(Killip II 10% O2 versus 1% air group, P
= 0.08)
2. Time to revascularisation 41 minutes
shorter in the air group
Wilson 1997
Methods Randomised, open-label, controlled trial
Participants People with confirmed AMI presenting within 24 h of onset of symptoms
Clinical setting: single-site coronary care unit in the UK
N randomised = 50. N analysed = 42 (dropouts: 1 death, 1 stroke, 4 withdrew consent,
2 incomplete data collection)
Mean age: oxygen 65 years, air 64 years
Sex: 59% men
Interventions Oxygen by face mask at 4 L/min versus normal air over 24 h
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Wilson 1997 (Continued)
Outcomes 24 hours for Hypoxaemia, arrhythmias, cardiac enzymes.
Exclusions People with heart failure, cyanosis central or pulmonary disease requiring O2
Length of follow-up Discharge
Clinical Context and parallel care Thrombolysis period
Notes The primary purpose of this trial was to look at the effect of oxygen on hypoxaemia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Sealed envelopes for randomisation
Blinding (performance bias and detection
bias)
Death
Low risk This was an open-label trial (but the absence
of blinding is unlikely to introduce bias in
this outcome)
Blinding (performance bias and detection
bias)
Pain (or surrogate)
High risk This was an open-label trial, therefore the
risk of bias in this outcome cannot be ruled
out
Blinding (performance bias and detection
bias)
infarct size ECG
Unclear risk Not relevant to this study
Incomplete outcome data (attrition bias)
Death
High risk 8 out of 50 missing data (group not speci-
fied); 1 death, 1 stroke, 4 withdrew consent,
2 incomplete data
Incomplete outcome data (attrition bias)
Infacrt size (Biochemical methods)
Unclear risk Not relevant in this study
Incomplete outcome data (attrition bias)
infarct size ECG mapping
Unclear risk Not relevant in this study
Incomplete outcome data (attrition bias)
Infarct size (MRI)
Unclear risk Not relevant in this study
Selective reporting (reporting bias) High risk The main variables of the study were in-
cidence and degree of hypoxaemia and the
effect of oxygen administration. The main
outcome of this review (death) was not re-
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Wilson 1997 (Continued)
ported, and in fact the only participant who
died was not included in the analysis
Other bias Low risk Other biases were not identified
Baseline characteristics Low risk Consecutive participants, similar age, smok-
ing and diabetes
AMI: myocardial infarction; AUC: area under the curve; BNP: brain natriuretic peptide; COPD: chronic obstructive pulmonary
disease; ECG: electrocardiogram; MC: medium concentration: MRI: magnetic resonance imaging; PCI: percutaneous coronary
intervention; PCA:percutaneous coronary angioplaty. SD: standard deviation; STEMI: ST-segment elevation myocardial infarction.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
AMIHOT 2003 Wrong intervention: aqueous oxygen therapy in STEMI
Dekleva 2004 Wrong intervention: hyperbaric oxygen versus air in participants after thrombolysis in AMI
Dotsenko 2007 Wrong intervention: hyperbaric oxygen versus air in conventionally treated participants with AMI
Haude 2007 Wrong intervention: supersaturated oxygen therapy after percutaneous coronary intervention in AMI
Kerr 1975 Different intervention: nitrous oxide 50% with or without oxygen 50% versus air in participants with AMI
Shandling 1997 Wrong intervention: hyperbaric oxygen
Slagboom 2005 Wrong intervention: haemoglobin-based oxygen therapeutics in elective PCI
AMI: acute myocardial infarction; PCI: percutaneous coronary intervention; PCA: percuaneous coronary angioplasty; STEMI: ST-
segment elevation myocardial infarction.
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Characteristics of ongoing studies [ordered by study ID]
ACTRN12609000466246
Trial name or title A randomised controlled trial comparing controlled oxygen therapy versus high flow oxygen therapy for acute
myocardial infarctions in the pre-hospital setting (no specific name available)
Methods Randomised controlled trial, parallel design with open label and allocation concealment
Participants People with chest pain and suspicion of acute coronary syndrome attended by Tasmanian ambulance service
in the Launceston region
Interventions High flow oxygen 8-15 L/min by non-breather mask compared to oxygen therapy to maintain oxygen
saturation between 92%-96%
Outcomes Primary outcome: mortality during ambulance or in the hospital stay
Secondary outcomes:
1. Time to resolution of chest pain using a 0-10 scale and an electronic system for reporting data
2. Length of hospital stay
Starting date Theoretically January 2012
Contact information Dr Michael Austin, Menzies Research Institute (Private Bag 23) Hobart TAS 7001. maaustin@utas.edu.au
Notes Not recruiting yet (register visited last time 30 June 2016)
NCT01423929
Trial name or title Supplemental oxygen in catheterization coronary emergency reperfusion (SOCCER)
Methods Multicentre single-blind randomised controlled trial, parallel design and allocation concealment
Participants Normoxic STEMI ambulance patients with symptom duration less than 6 hours (bypassing the emergency
department)
Interventions Oxygen 10 L/min by oxymask versus room air
Outcomes Primary outcomes: infarct size estimated by MRI at day 4, myocardial salvage index by MRI
Secondary outcomes: TIMI flow during PCI, echocardiography (acute and 6 months after AMI), pro-BNP,
and dose of opioids
Starting date January 2012
Contact information Mahin Akbarzadeh (Skåne University Hospital at Lund)
Notes 2 hospitals with PPCI capabilities. Verbal informed consent in ambulance and delayed written informed
consent
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NCT01787110
Trial name or title An efficacy and outcome study of supplemental oxygen treatment in patients with suspected myocardial
infarction (DETO2X-AMI)
Methods Multicentre open label registry-based randomised clinical trial
Participants Normoxic patients (saturation > 90%) in emergencymedical service or emergency departments with suspicion
of acute myocardial infarction (STEMI and non STEMI) within the last 6 h
Interventions Oxygen 6 L/min by oxymask started as soon as possible and maintained for 13 h vs no oxygen except if
saturation < 90% (repeatedly checked)
Outcomes Primary outcome: 1 year all-cause mortality.
Secondary outcomes: 30-days mortality, major cardiac coronary events (MACE) in 30 days and 1 year
including reinfarction and hospitalisations for cardiac failure
In sub-studies, echocardiograpy and cardiac magnetic resonance will be used to assess infarct size and cardiac
function
Starting date April 2013
Contact information Leif Svensson and Robin Hofmann (Södersjukhuset. Stockholm, Sweden, 11883)
Notes The protocol and feasibility studies have been published (see ongoing trials)
NCT02290080
Trial name or title Determination of the role of oxygen in suspected acute myocardial infarction by biomarkers (DETO2X-bio)
Methods Single blind (outcomes assessor) randomised clinical trial
Participants Normoxic patients (saturation > 90%) in emergencymedical service or emergency departments with suspicion
of acute myocardial infarction (STEMI and non STEMI) within the last 6 h
Interventions Oxygen 6 L/min by oxymask started as soon as possible and maintained for 13 h vs no oxygen except if
saturation < 90% (repeatedly checked)
Outcomes Plasma concentration levels over time of biomarkers of oxidative stress, apoptosis, inflammation and platelet
aggregation
Starting date October 2014 (estimated study completion October 2015)
Contact information Leif Svensson & Robin Hofmann (Södersjukhuset. Stockholm, Sweden, 11883
Notes This study is a substudy of DETO2X-AMI
AMI: acute myocardial infarction; BNP: brain natriuretic peptide; MRI: magnetic resonance imaging; PCI: percutaneous coronary
intervention; TIMI: thrombolysis in myocardial infarction.
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D A T A A N D A N A L Y S E S
Comparison 1. Oxygen versus air
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality in hospital
for participants with AMI
(fixed-effect)
4 871 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.52, 1.98]
2 All-cause mortality in hospital
for participants with AMI
(random-effects)
4 871 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.34, 3.59]
3 All-cause mortality in hospital
for all participants (including
those who did not have an
AMI) (fixed-effect)
4 1123 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.50, 1.95]
4 All-cause mortality in hospital
for all participants (including
those who did not have an
AMI)(random-effects)
4 1123 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.34, 3.39]
5 All-cause mortality in hospital
for all participants (including
those who did not have an
AMI) and including Wilson
trial- worse case analysis)
5 1173 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.54, 2.02]
6 All-cause mortality in hospital
for all participants (including
those who did not have an
AMI and including Wilson
trial- best case analysis )
5 1173 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.49, 1.80]
7 All-cause mortality in hospital
for all participants (including
those who did not have
AMI and including the two
participants of Ranchord study
with cardiogenic shock who
died). Worse-case analysis.
4 1123 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.58, 2.15]
8 All-cause mortality in hospital
for all participants (including
those who did not have
AMI and including the two
participants of Ranchord study
with cardiogenic shock who
died). Best-case analysis
4 1123 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.46, 1.71]
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9 All-cause mortality in hospital
for all participants (including
those who did not have
an AMI) trials done in the
revascularisation era
3 923 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.24, 1.39]
10 Cardiac failure 2 775 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.50, 1.55]
11 Recurrent myocardial
infarction (or ischaemia)
2 578 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.94, 2.99]
12 Opiate use (as a proxy measure
for pain) for participants with
an AMI (fixed-effect)
2 199 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.83, 1.18]
13 Opiate use (as a proxy measure
for pain) for participants with
an AMI (random-effects)
2 199 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.72, 1.23]
14 Opiate use (as a proxy measure
for pain) for all participants on
ITT (including those who did
not have an AMI) (fixed-effect)
2 250 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.78, 1.20]
15 Opiate use (as a proxy measure
for pain) for all participants
on ITT (including those
who did not have an AMI)
(random-effects)
2 250 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.78, 1.38]
16 Major bleeding 1 441 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.56, 4.24]
Analysis 1.1. Comparison 1 Oxygen versus air, Outcome 1 All-cause mortality in hospital for participants
with AMI (fixed-effect).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 1 All-cause mortality in hospital for participants with AMI (fixed-effect)
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rawles 1976 9/80 3/77 18.7 % 2.89 [ 0.81, 10.27 ]
Ukholkina 2005 1/58 0/79 2.6 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/68 2/68 12.2 % 0.50 [ 0.05, 5.39 ]
Stub 2015 5/218 11/223 66.5 % 0.46 [ 0.16, 1.32 ]
Total (95% CI) 424 447 100.0 % 1.02 [ 0.52, 1.98 ]
Total events: 16 (Oxygen), 16 (Air)
Heterogeneity: Chi2 = 5.84, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Oxygen versus air, Outcome 2 All-cause mortality in hospital for participants
with AMI (random-effects).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 2 All-cause mortality in hospital for participants with AMI (random-effects)
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rawles 1976 9/80 3/77 33.6 % 2.89 [ 0.81, 10.27 ]
Ukholkina 2005 1/58 0/79 11.0 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/68 2/68 17.0 % 0.50 [ 0.05, 5.39 ]
Stub 2015 5/218 11/223 38.4 % 0.46 [ 0.16, 1.32 ]
Total (95% CI) 424 447 100.0 % 1.10 [ 0.34, 3.59 ]
Total events: 16 (Oxygen), 16 (Air)
Heterogeneity: Tau2 = 0.66; Chi2 = 5.84, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Oxygen versus air, Outcome 3 All-cause mortality in hospital for all participants
(including those who did not have an AMI) (fixed-effect).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 3 All-cause mortality in hospital for all participants (including those who did not have an AMI) (fixed-effect)
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rawles 1976 9/105 3/95 19.1 % 2.71 [ 0.76, 9.73 ]
Ukholkina 2005 1/58 0/79 2.6 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/72 2/76 11.8 % 0.53 [ 0.05, 5.70 ]
Stub 2015 5/318 11/320 66.5 % 0.46 [ 0.16, 1.30 ]
Total (95% CI) 553 570 100.0 % 0.99 [ 0.50, 1.95 ]
Total events: 16 (Oxygen), 16 (Air)
Heterogeneity: Chi2 = 5.52, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Oxygen versus air, Outcome 4 All-cause mortality in hospital for all participants
(including those who did not have an AMI)(random-effects).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 4 All-cause mortality in hospital for all participants (including those who did not have an AMI)(random-effects)
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rawles 1976 9/105 3/95 33.7 % 2.71 [ 0.76, 9.73 ]
Ukholkina 2005 1/58 0/79 10.6 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/72 2/76 16.6 % 0.53 [ 0.05, 5.70 ]
Stub 2015 5/318 11/320 39.1 % 0.46 [ 0.16, 1.30 ]
Total (95% CI) 553 570 100.0 % 1.08 [ 0.34, 3.39 ]
Total events: 16 (Oxygen), 16 (Air)
Heterogeneity: Tau2 = 0.59; Chi2 = 5.52, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Oxygen versus air, Outcome 5 All-cause mortality in hospital for all participants
(including those who did not have an AMI) and including Wilson trial- worse case analysis).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 5 All-cause mortality in hospital for all participants (including those who did not have an AMI) and including Wilson trial- worse case analysis)
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rawles 1976 9/105 3/95 18.5 % 2.71 [ 0.76, 9.73 ]
Wilson 1997 1/25 0/25 2.9 % 3.00 [ 0.13, 70.30 ]
Ukholkina 2005 1/58 0/79 2.5 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/72 2/76 11.5 % 0.53 [ 0.05, 5.70 ]
Stub 2015 5/318 11/320 64.6 % 0.46 [ 0.16, 1.30 ]
Total (95% CI) 578 595 100.0 % 1.05 [ 0.54, 2.02 ]
Total events: 17 (Oxygen), 16 (Air)
Heterogeneity: Chi2 = 5.99, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Oxygen versus air, Outcome 6 All-cause mortality in hospital for all participants
(including those who did not have an AMI and including Wilson trial- best case analysis ).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 6 All-cause mortality in hospital for all participants (including those who did not have an AMI and including Wilson trial- best case analysis )
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rawles 1976 9/105 3/95 17.5 % 2.71 [ 0.76, 9.73 ]
Wilson 1997 0/25 1/25 8.3 % 0.33 [ 0.01, 7.81 ]
Ukholkina 2005 1/58 0/79 2.4 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/72 2/76 10.8 % 0.53 [ 0.05, 5.70 ]
Stub 2015 5/318 11/320 61.0 % 0.46 [ 0.16, 1.30 ]
Total (95% CI) 578 595 100.0 % 0.94 [ 0.49, 1.80 ]
Total events: 16 (Oxygen), 17 (Air)
Heterogeneity: Chi2 = 5.92, df = 4 (P = 0.20); I2 =32%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Oxygen versus air, Outcome 7 All-cause mortality in hospital for all participants
(including those who did not have AMI and including the two participants of Ranchord study with cardiogenic
shock who died). Worse-case analysis..
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 7 All-cause mortality in hospital for all participants (including thosewho did not have AMI and including the two participants of Ranchord studywith cardiogenic
shock who died). Worse-case analysis.
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rawles 1976 9/105 3/95 19.1 % 2.71 [ 0.76, 9.73 ]
Ukholkina 2005 1/58 0/79 2.6 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 3/72 2/76 11.8 % 1.58 [ 0.27, 9.20 ]
Stub 2015 5/318 11/320 66.5 % 0.46 [ 0.16, 1.30 ]
Total (95% CI) 553 570 100.0 % 1.11 [ 0.58, 2.15 ]
Total events: 18 (Oxygen), 16 (Air)
Heterogeneity: Chi2 = 5.44, df = 3 (P = 0.14); I2 =45%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Oxygen versus air, Outcome 8 All-cause mortality in hospital for all participants
(including those who did not have AMI and including the two participants of Ranchord study with cardiogenic
shock who died). Best-case analysis.
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 8 All-cause mortality in hospital for all participants (including thosewho did not have AMI and including the two participants of Ranchord studywith cardiogenic
shock who died). Best-case analysis
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rawles 1976 9/105 3/95 17.1 % 2.71 [ 0.76, 9.73 ]
Ukholkina 2005 1/58 0/79 2.3 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/72 4/76 21.1 % 0.26 [ 0.03, 2.31 ]
Stub 2015 5/318 11/320 59.5 % 0.46 [ 0.16, 1.30 ]
Total (95% CI) 553 570 100.0 % 0.89 [ 0.46, 1.71 ]
Total events: 16 (Oxygen), 18 (Air)
Heterogeneity: Chi2 = 6.57, df = 3 (P = 0.09); I2 =54%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Oxygen versus air, Outcome 9 All-cause mortality in hospital for all participants
(including those who did not have an AMI) trials done in the revascularisation era.
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 9 All-cause mortality in hospital for all participants (including those who did not have an AMI) trials done in the revascularisation era
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ukholkina 2005 1/58 0/79 3.2 % 4.07 [ 0.17, 98.10 ]
Ranchord 2012 1/72 2/76 14.6 % 0.53 [ 0.05, 5.70 ]
Stub 2015 5/318 11/320 82.2 % 0.46 [ 0.16, 1.30 ]
Total (95% CI) 448 475 100.0 % 0.58 [ 0.24, 1.39 ]
Total events: 7 (Oxygen), 13 (Air)
Heterogeneity: Chi2 = 1.64, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Oxygen versus air, Outcome 10 Cardiac failure.
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 10 Cardiac failure
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stub 2015 20/318 20/320 82.5 % 1.01 [ 0.55, 1.83 ]
Ukholkina 2005 1/58 5/79 17.5 % 0.27 [ 0.03, 2.27 ]
Total (95% CI) 376 399 100.0 % 0.88 [ 0.50, 1.55 ]
Total events: 21 (Oxygen), 25 (Air)
Heterogeneity: Chi2 = 1.37, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Oxygen versus air, Outcome 11 Recurrent myocardial infarction (or
ischaemia).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 11 Recurrent myocardial infarction (or ischaemia)
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stub 2015 12/218 2/223 12.7 % 6.14 [ 1.39, 27.10 ]
Ukholkina 2005 12/58 16/79 87.3 % 1.02 [ 0.52, 1.99 ]
Total (95% CI) 276 302 100.0 % 1.67 [ 0.94, 2.99 ]
Total events: 24 (Oxygen), 18 (Air)
Heterogeneity: Chi2 = 5.04, df = 1 (P = 0.02); I2 =80%
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Oxygen versus air, Outcome 12 Opiate use (as a proxy measure for pain) for
participants with an AMI (fixed-effect).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 12 Opiate use (as a proxy measure for pain) for participants with an AMI (fixed-effect)
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wilson 1997 16/22 18/20 26.2 % 0.81 [ 0.60, 1.08 ]
Rawles 1976 57/80 52/77 73.8 % 1.06 [ 0.86, 1.30 ]
Total (95% CI) 102 97 100.0 % 0.99 [ 0.83, 1.18 ]
Total events: 73 (Oxygen), 70 (Air)
Heterogeneity: Chi2 = 2.18, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Oxygen versus air, Outcome 13 Opiate use (as a proxy measure for pain) for
participants with an AMI (random-effects).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 13 Opiate use (as a proxy measure for pain) for participants with an AMI (random-effects)
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rawles 1976 57/80 52/77 57.6 % 1.06 [ 0.86, 1.30 ]
Wilson 1997 16/22 18/20 42.4 % 0.81 [ 0.60, 1.08 ]
Total (95% CI) 102 97 100.0 % 0.94 [ 0.72, 1.23 ]
Total events: 73 (Oxygen), 70 (Air)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.18, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Oxygen versus air, Outcome 14 Opiate use (as a proxy measure for pain) for
all participants on ITT (including those who did not have an AMI) (fixed-effect).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 14 Opiate use (as a proxy measure for pain) for all participants on ITT (including those who did not have an AMI) (fixed-effect)
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rawles 1976 57/105 52/95 75.2 % 0.99 [ 0.77, 1.28 ]
Wilson 1997 16/25 18/25 24.8 % 0.89 [ 0.61, 1.30 ]
Total (95% CI) 130 120 100.0 % 0.97 [ 0.78, 1.20 ]
Total events: 73 (Oxygen), 70 (Air)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Oxygen versus air, Outcome 15 Opiate use (as a proxy measure for pain) for
all participants on ITT (including those who did not have an AMI) (random-effects).
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 15 Opiate use (as a proxy measure for pain) for all participants on ITT (including those who did not have an AMI) (random-effects)
Study or subgroup Oxygen Air
Risk
Ratio(Non-
event) Weight
Risk
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rawles 1976 57/105 52/95 87.9 % 1.01 [ 0.75, 1.37 ]
Wilson 1997 16/25 18/25 12.1 % 1.29 [ 0.57, 2.91 ]
Total (95% CI) 130 120 100.0 % 1.04 [ 0.78, 1.38 ]
Total events: 73 (Oxygen), 70 (Air)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Oxygen versus air, Outcome 16 Major bleeding.
Review: Oxygen therapy for acute myocardial infarction
Comparison: 1 Oxygen versus air
Outcome: 16 Major bleeding
Study or subgroup Oxygen Air Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Stub 2015 9/218 6/223 100.0 % 1.53 [ 0.56, 4.24 ]
Total (95% CI) 218 223 100.0 % 1.53 [ 0.56, 4.24 ]
Total events: 9 (Oxygen), 6 (Air)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search strategies 2010
CENTRAL in the Cochrane Library
#1 MeSH descriptor Myocardial Infarction explode all trees
#2 myocardial next infarct*
#3 heart next infarct*
#4 (acute near/3 coronary )
#5 (coronary near/3 syndrome* )
#6 heart next attack*
#7 MeSH descriptor Coronary Thrombosis this term only
#8 coronary near/3 thrombosis
#9 ami
#10 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)
#11 MeSH descriptor Oxygen Inhalation Therapy explode all trees
#12 oxygen
#13 (#10 and #12)
MEDLINE (OVID)
1 exp Myocardial Infarction/
2 myocardial infarct$.tw.
3 heart attack$.tw.
4 heart infarct$.tw.
5 (coronary adj3 syndrome$).tw.
6 acute coronary.tw.
7 Coronary Thrombosis/
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 Oxygen Inhalation Therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.13 oxygen.ti. or Oxygenotherapy/
14 or/11-13
15 10 and 14
16 randomized controlled trial.pt.
17 controlled clinical trial.pt.
18 randomized controlled trials.sh.
19 random allocation.sh.
20 double blind method.sh.
21 single-blind method.sh.
22 or/16-21
23 (animals not humans).sh.
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24 22 not 23
25 clinical trial.pt.
26 exp clinical trials/
27 (clin$ adj25 trial$).ti,ab.
28 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
29 placebos.sh.
30 placebo$.ti,ab.
31 random$.ti,ab.
32 research design.sh.
33 or/25-32
34 33 not 23
35 34 not 24
36 comparative study.sh.
37 exp evaluation studies/
38 follow up studies.sh.
39 prospective studies.sh.
40 (control$ or prospectiv$ or volunteer$).ti,ab.
41 or/36-40
42 41 not 23
43 42 not (24 or 35)
44 24 or 35 or 43
45 15 and 44
Embase (OVID)
1 exp Heart Infarction/
2 Coronary Artery Thrombosis/
3 myocardial infarct$.tw.
4 heart attack$.tw.
5 heart infarct$.tw.
6 (coronary adj3 syndrome$).tw.
7 acute coronary.tw.
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 oxygen therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.
13 oxygen.ti.
14 or/11-13
15 10 and 14
Pascal
1 oxygen.mp. [mp=abstract, descriptors - english, descriptors - french, descriptors - spanish, heading words, identifiers - english,
identifiers - french, identifiers - spanish, title, translated title]
2 myocardial infarction.mp. [mp=abstract, descriptors - english, descriptors - french, descriptors - spanish, heading words, identifiers -
english, identifiers - french, identifiers - spanish, title, translated title]
3 acute coronary syndrome.mp. [mp=abstract, descriptors - english, descriptors - french, descriptors - spanish, heading words, identifiers
- english, identifiers - french, identifiers - spanish, title, translated title]
4 2 or 3
5 1 and 4
6 random$.mp. [mp=abstract, descriptors - english, descriptors - french, descriptors - spanish, heading words, identifiers - english,
identifiers - french, identifiers - spanish, title, translated title]
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7 5 and 6
CINAHL (EBSCO)
(heart attack* or MI or AMI or heart infarct* or myocardial infarct* or coronary syndrome or coronary thrombosis) AND ((oxygen)
AND (random* or control* or trial*)
LILACS (BIREME)
(heart or MI or AMI or myocardial or coronary) AND (oxygen) AND (random* or control* or trial*)
ISI Proceedings (Web of Knowledge)
(heart or MI or AMI or myocardial or coronary) AND (oxygen) AND (random* or control* or trial*)
Appendix 2. Search strategies 2012
CENTRAL
#1 MeSH descriptor Myocardial Infarction explode all trees
#2 (myocardial infarct*)
#3 (heart attack*)
#4 (heart infarct*)
#5 (coronary near/3 syndrome*)
#6 ”acute coronary“
#7 MeSH descriptor Coronary Thrombosis, this term only
#8 ”coronary thrombosis“
#9 (ami)
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Oxygen Inhalation Therapy, this term only
#12 (oxygen near/3 (therapy or treat* or effect* or admin* or inhal*))
#13 (oxygen):ti
#14 (oxygenotherapy)
#15 (#11 OR #12 OR #13 OR #14)
#16 (#10 AND #15), from 2010 to 2012
MEDLINE (OVID)
1 exp Myocardial Infarction/
2 myocardial infarct$.tw.
3 heart attack$.tw.
4 heart infarct$.tw.
5 (coronary adj3 syndrome$).tw.
6 acute coronary.tw.
7 Coronary Thrombosis/
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 Oxygen Inhalation Therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.
13 oxygen.ti. or Oxygenotherapy.tw.
14 or/11-13
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15 10 and 14
16 randomized controlled trial.pt.
17 controlled clinical trial.pt.
18 randomized.ab.
19 placebo.ab.
20 drug therapy.fs.
21 randomly.ab.
22 trial.ab.
23 groups.ab.
24 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 exp animals/ not humans.sh.
26 24 not 25
27 15 and 26
28 limit 27 to yr=”2010 -Current“
Embase (OVID)
1 exp Myocardial Infarction/
2 myocardial infarct$.tw.
3 heart attack$.tw.
4 heart infarct$.tw.
5 (coronary adj3 syndrome$).tw.
6 acute coronary.tw.
7 Coronary Thrombosis/
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 Oxygen Inhalation Therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.
13 oxygen.ti. or Oxygenotherapy.tw.
14 or/11-13
15 10 and 14
16 random$.tw.
17 factorial$.tw.
18 crossover$.tw.
19 cross over$.tw.
20 cross-over$.tw.
21 placebo$.tw.
22 (doubl$ adj blind$).tw.
23 (singl$ adj blind$).tw.
24 assign$.tw.
25 allocat$.tw.
26 volunteer$.tw.
27 crossover procedure/
28 double blind procedure/
29 randomized controlled trial/
30 single blind procedure/
31 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32 (animal/ or nonhuman/) not human/
33 31 not 32
34 15 and 33
35 limit 34 to yr=”2010 -Current“
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CINAHL
S19 S14 and S17 Limiters - Published Date from: 20100101-20120731
S18 S14 and S17
S17 S15 or S16
S16 (MH ”Randomized Controlled Trials“)
S15 random* or blind* or allocat* or trial* or placebo* or crossover* or cross-over*
S14 S10 and S13
S13 S11 or S12
S12 oxygen or oxygenotherapy
S11 (MH ”Oxygen Therapy+“)
S10 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9
S9 ami
S8 coronary N3 thrombosis
S7 (MH ”Coronary Thrombosis“)
S6 (heart attack*)
S5 (coronary N3 syndrome* )
S4 (acute N3 coronary )
S3 (heart infarct*)
S2 (myocardial infarct*)
S1 (MH ”Myocardial Infarction+“)
Web of Science
#14 #13 AND #12 AND #8
#13 Topic=((random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*))
#12 #11 OR #10 OR #9
#11 Topic=(oxygenotherapy)
#10 Title=((oxygen near/3 (therapy or treat* or effect* or admin* or inhal*)))
#9 Title=(oxygen)
#8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#7 Topic=(ami)
#6 Topic=(coronary near/3 thrombosis)
#5 Topic=((heart attack*))
#4 Topic=((coronary near/3 syndrome* ))
#3 Topic=((acute near/3 coronary ))
#2 Topic=((heart infarct*))
#1 Topic=((myocardial infarct*))
Appendix 3. Search strategies 2015
CENTRAL
#1 MeSH descriptor: [Myocardial Infarction] explode all trees
#2 myocardial infarct*
#3 heart attack*
#4 heart infarct*
#5 (coronary near/3 syndrome*)
#6 ”acute coronary“
#7 MeSH descriptor: [Coronary Thrombosis] this term only
#8 ”coronary thrombosis“
#9 ami
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 MeSH descriptor: [Oxygen Inhalation Therapy] this term only
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#12 (oxygen near/3 (therapy or treat* or effect* or admin* or inhal*))
#13 oxygen:ti
#14 oxygenotherapy
#15 #11 or #12 or #13 or #14
#16 #10 and #15 Publication Year from 2012 to 2015
MEDLINE OVID
1 exp Myocardial Infarction/
2 myocardial infarct$.tw.
3 heart attack$.tw.
4 heart infarct$.tw.
5 (coronary adj3 syndrome$).tw.
6 acute coronary.tw.
7 Coronary Thrombosis/
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 Oxygen Inhalation Therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.
13 oxygen.ti. or Oxygenotherapy.tw.
14 or/11-13
15 10 and 14
16 randomized controlled trial.pt.
17 controlled clinical trial.pt.
18 randomized.ab.
19 placebo.ab.
20 drug therapy.fs.
21 randomly.ab.
22 trial.ab.
23 groups.ab.
24 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 exp animals/ not humans.sh.
26 24 not 25
27 15 and 26
28 limit 27 to yr=”2012 -Current“
Embase OVID
1 exp Myocardial Infarction/
2 myocardial infarct$.tw.
3 heart attack$.tw.
4 heart infarct$.tw.
5 (coronary adj3 syndrome$).tw.
6 acute coronary.tw.
7 Coronary Thrombosis/
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 Oxygen Inhalation Therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.
13 oxygen.ti. or Oxygenotherapy.tw.
14 or/11-13
15 10 and 14
16 random$.tw.
17 factorial$.tw.
18 crossover$.tw.
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19 cross over$.tw.
20 cross-over$.tw.
21 placebo$.tw.
22 (doubl$ adj blind$).tw.
23 (singl$ adj blind$).tw.
24 assign$.tw.
25 allocat$.tw.
26 volunteer$.tw.
27 crossover procedure/
28 double blind procedure/
29 randomized controlled trial/
30 single blind procedure/ (16122)
31 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32 (animal/ or nonhuman/) not human/
33 31 not 32
34 15 and 33
35 limit 34 to yr=”2012 - 2015“
CINAHL Plus (EBSCO)
S19 S14 and S17 Limiters - Published Date from: 20120701-20150603
S18 S14 and S17
S17 S15 or S16
S16 (MH ”Randomized Controlled Trials“)
S15 random* or blind* or allocat* or trial* or placebo* or crossover* or cross-over*
S14 S10 and S13
S13 S11 or S12
S12 oxygen or oxygenotherapy
S11 (MH ”Oxygen Therapy+“)
S10 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9
S9 ami
S8 coronary N3 thrombosis
S7 (MH ”Coronary Thrombosis“)
S6 (heart attack*)
S5 (coronary N3 syndrome* )
S4 (acute N3 coronary )
S3 (heart infarct*)
S2 (myocardial infarct*)
S1 (MH ”Myocardial Infarction+“)
Web of Science (Thomson Reuters)
RCT filter adapted from Cochrane RCT filter.
#14 #13 AND #12 AND #8
#13 TS=((random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*))
#12 #11 OR #10 OR #9
#11 TS=(oxygenotherapy)
#10 TS=((oxygen near/3 (therapy or treat* or effect* or admin* or inhal*)))
#9 TS=(oxygen)
#8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#7 TS=(ami)
#6 TS=(coronary near/3 thrombosis)
#5 TS=((heart attack*))
#4 TS=((coronary near/3 syndrome* ))
#3 TS=((acute near/3 coronary ))
#2 TS=((heart infarct*))
#1 TS=((myocardial infarct*))
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PubMed
Search ((((((publisher[sb] NOT pubstatusnihms)))) AND ( ”2012/01/01“[PDat] : ”2015/12/31“[PDat] ))) AND (((((((((Oxygen In-
halation Therapy[MeSH Major Topic]) OR ((oxygen n3 (therapy or treat* or effect* or admin* or inhal*)))) OR oxygen[Title]) OR
oxygenotherapy)) AND (((myocardial infarct* or heart attack* or heart infarct* or (coronary n3 syndrome) or ”acute coronary“ or ”coro-
nary thrombosis“ or ami)) OR Coronary Thrombosis[MeSH Major Topic]))) AND ((((((((((randomized controlled trial[Publication
Type]) OR controlled clinical trial[Publication Type]) OR randomized[Title/Abstract]) OR placebo[Title/Abstract]) OR drug ther-
apy[MeSH Subheading]) OR randomly[Title/Abstract]) OR trial[Title/Abstract]) OR groups[Title/Abstract])) NOT ((animals[MeSH
Terms]) NOT humans[MeSH Terms]))) AND ( ”2012/01/01“[PDat] : ”2015/12/31“[PDat] )) Filters: Publication date from 2012/
01/01 to 2015/12/31
LILACS. Latin American and Caribbean Health Sciences Literature (BIREME)
(tw:(myocardial infarctionORCoronaryDiseaseORMyocardiumORHeart Failure)) AND(tw:(Oxygen$”OROxygenConsumption
OR Oxygen Inhalation Therapy)) AND (year˙cluster:(“2013” OR “2014” OR “2015”)
Appendix 4. Search strategies 2016
CENTRAL
#1 MeSH descriptor: [Myocardial Infarction] explode all trees
#2 myocardial infarct*
#3 heart attack*
#4 heart infarct*
#5 (coronary near/3 syndrome*)
#6 ”acute coronary“
#7 MeSH descriptor: [Coronary Thrombosis] this term only
#8 ”coronary thrombosis“
#9 ami
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 MeSH descriptor: [Oxygen Inhalation Therapy] this term only
#12 (oxygen near/3 (therapy or treat* or effect* or admin* or inhal*))
#13 oxygen:ti
#14 oxygenotherapy
#15 #11 or #12 or #13 or #14
#16 #10 and #15 Publication Year from 2012 to 2016
MEDLINE OVID
1 exp Myocardial Infarction/
2 myocardial infarct$.tw.
3 heart attack$.tw.
4 heart infarct$.tw.
5 (coronary adj3 syndrome$).tw.
6 acute coronary.tw.
7 Coronary Thrombosis/
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 Oxygen Inhalation Therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.
13 oxygen.ti. or Oxygenotherapy.tw.
14 or/11-13
15 10 and 14
16 randomized controlled trial.pt.
17 controlled clinical trial.pt.
18 randomized.ab.
19 placebo.ab.
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20 drug therapy.fs.
21 randomly.ab.
22 trial.ab.
23 groups.ab.
24 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 exp animals/ not humans.sh.
26 24 not 25
27 15 and 26
28 limit 27 to yr=”2012 -Current“
EMBASE OVID
1 exp Myocardial Infarction/
2 myocardial infarct$.tw.
3 heart attack$.tw.
4 heart infarct$.tw.
5 (coronary adj3 syndrome$).tw.
6 acute coronary.tw.
7 Coronary Thrombosis/
8 coronary thrombosis.tw.
9 ami.tw.
10 or/1-9
11 Oxygen Inhalation Therapy/
12 (oxygen adj3 (therapy or treat$ or effect$ or admin$ or inhal$)).tw.
13 oxygen.ti. or Oxygenotherapy.tw.
14 or/11-13
15 10 and 14
16 random$.tw.
17 factorial$.tw.
18 crossover$.tw.
19 cross over$.tw.
20 cross-over$.tw.
21 placebo$.tw.
22 (doubl$ adj blind$).tw.
23 (singl$ adj blind$).tw.
24 assign$.tw.
25 allocat$.tw.
26 volunteer$.tw.
27 crossover procedure/
28 double blind procedure/
29 randomized controlled trial/
30 single blind procedure/ (16122)
31 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32 (animal/ or nonhuman/) not human/
33 31 not 32
34 15 and 33
35 limit 34 to yr=”2012 - 2016“
Cinahl Plus (EBSCO)
S19 S14 and S17 Limiters - Published Date from: 20120701-20160606
S18 S14 and S17
S17 S15 or S16
S16 (MH ”Randomized Controlled Trials“)
S15 random* or blind* or allocat* or trial* or placebo* or crossover* or cross-over*
S14 S10 and S13
S13 S11 or S12
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S12 oxygen or oxygenotherapy
S11 (MH ”Oxygen Therapy+“)
S10 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9
S9 ami
S8 coronary N3 thrombosis
S7 (MH ”Coronary Thrombosis“)
S6 (heart attack*)
S5 (coronary N3 syndrome* )
S4 (acute N3 coronary )
S3 (heart infarct*)
S2 (myocardial infarct*)
S1 (MH ”Myocardial Infarction+“)
Web of Science (ISI)
RCT filter adapted from Cochrane RCT filter.
#14 #13 AND #12 AND #8
#13 TS=((random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*))
#12 #11 OR #10 OR #9
#11 TS=(oxygenotherapy)
#10 TS=((oxygen near/3 (therapy or treat* or effect* or admin* or inhal*)))
#9 TS=(oxygen)
#8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#7 TS=(ami)
#6 TS=(coronary near/3 thrombosis)
#5 TS=((heart attack*))
#4 TS=((coronary near/3 syndrome* ))
#3 TS=((acute near/3 coronary ))
#2 TS=((heart infarct*))
#1 TS=((myocardial infarct*))
PubMed
(publisher[sb] NOT pubstatusnihms) AND ( ”2015/01/01“[PDat] : ”2016/12/31“[PDat]) AND
(Oxygen InhalationTherapy[MeSHMajor Topic])OR (oxygen n3 (therapy or treat* or effect* or admin* or inhal*))OR (oxygen[Title])
OR oxygenotherapy) AND
(myocardial infarct* or heart attack* or heart infarct* or (coronary n3 syndrome) or ”acute coronary“ or ”coronary thrombosis“ or ami)
OR Coronary Thrombosis[MeSH Major Topic]) AND
(((randomized controlled trial[Publication Type]) OR (controlled clinical trial[Publication Type]) OR randomized[Title/Abstract] OR
placebo[Title/Abstract] OR drug therapy[MeSH Subheading] OR randomly[Title/Abstract] OR trial[Title/Abstract] OR groups[Title/
Abstract]) NOT ((animals[MeSH Terms]) NOT humans[MeSH Terms])) AND ( ”2015/01/01“[PDat] : ”2016/12/31“[PDat])
LILACS. Latin American and Caribbean Health Sciences Literature (BIREME)
(tw:(myocardial infarctionORCoronaryDiseaseORMyocardiumORHeart Failure)) AND(tw:(Oxygen$”OROxygenConsumption
OR Oxygen Inhalation Therapy)) AND (year˙cluster:(“2013” OR “2014” OR “2015” OR ”2016“)
WH A T ’ S N E W
Last assessed as up-to-date: 6 June 2016.
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Date Event Description
12 October 2016 New citation required but conclusions have not
changed
The addition of one new trial changed the results of this
review but not the conclusions
This version includes a ’Summary of findings’ table with
GRADE assessment, unlike the previous version
3 August 2015 New search has been performed We conducted a new search in June 2016 and identified
one new trial for inclusion along with four ongoing
trials
H I S T O R Y
Protocol first published: Issue 2, 2008
Review first published: Issue 6, 2010
Date Event Description
7 April 2013 New citation required but conclusions have not changed One new study included
7 April 2013 New search has been performed The updated search was conducted in May 2013, and
identified one new trial for inclusion and three ongoing
trials
C O N T R I B U T I O N S O F A U T H O R S
Juan Cabello provided expert advice, co-wrote the protocol and helped with quality assessment, contacted authors for further informa-
tion, data extraction, analysis, writing the discussion and entering data into RevMan.
Amanda Burls co-wrote the protocol, contacted authors for further information and contributed to quality assessment, data extraction,
analysis, writing the discussion, and entering data into RevMan.
Sue Bayliss undertook the electronic searches, helped obtain papers and proofread the review.
Jose Emparanza Knorr co-wrote the protocol and contributed to quality assessment, data extraction, analysis and writing of the
discussion.
TomQuinn provided expert advice, contacted experts to find unpublished studies and contributed to quality assessment, data extraction,
revision of the draft paper and writing of the discussion.
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D E C L A R A T I O N S O F I N T E R E S T
None on starting this review. After starting this systematic review two of the authors (AB and TQ) have put together, with other clinical
colleagues, a proposal for a randomised controlled trial in the UK of oxygen for AMI in the pre-hospital setting. This proposal was not
supported, and therefore the protocol was cancelled.
Tom Quinn was a member of the steering group for the STREAM Trial (Boehringer Ingelheim) and the EUROMAX trial (Medicines
Company), and he was a local collaborator/principal investigator for the ATLANTIC trial (Astra Zeneca). All of these were studies of
pre-hospital management of patients with acute coronary syndrome.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• None, Not specified.
No financial support was received for this review
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Data were too sparse to permit adequate analysis of the subgroups that had been prespecified for exploration.
We made three changes:
1. One minor change in the search strategy to improve the sensitivity, i.e. the inclusion of the text word ’oxygenotherapy’ in the
title (the original search failed to pick up the Russian article and we looked to see if it was in MEDLINE and, if so, why the search
strategy had missed it);
2. After the protocol was published, a new version of the Cochrane Handbook for Systematic Reviews of Interventions recommended a
new approach to assessment of risk of bias, so we changed our method of assessment to be consistent with the recommendations
(Higgins 2011).
3. In this version of the review, we have used the nine-point scale suggested by GRADE to classify the clinical importance of the
outcomes (Guyatt 2008).
4. In this version, we include the ’Summary of findings’ table with GRADE assessment, unlike the previous version.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
∗Oxygen Inhalation Therapy [adverse effects; mortality]; Air; Analgesics [therapeutic use]; Myocardial Infarction [mortality; ∗therapy];
Randomized Controlled Trials as Topic
MeSH check words
Humans
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